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Chapter 1: Literature review 







This narrative review aimed to summarise the literature on the use of point of care 
ultrasound (POCUS)-derived abnormalities in women with preeclampsia. The clinical 
utility of the biomarkers brain natriuretic peptide (BNP) and serum albumin is also 
discussed. 
2 Research strategy 
All publications used in this narrative review were obtained from the Pubmed database, 
and the literature includes studies published as recently as 2018. Keywords and terms used 
for the search included, but were not limited, “pregnancy”, “preeclampsia”, 
“echocardiography”, “point of care ultrasound”, “speckle tracking”, “optic nerve sheath 
diameter”, “brain natriuretic peptide”, “lung ultrasound”, “acid base disturbances” and 
“albumin”. Literature included was limited to the English language, and included 59 
publications.  
3 Introduction 
Point of care ultrasound (PoCUS) is a fast-growing clinical utility, and an essential clinical 
skill for all practitioners working with patients in the perioperative period. It has been 
adopted in multiple areas of medicine and is becoming the standard of care. This includes, 
but is not limited to anaesthesia, surgery, intensive care, gynaecology, general medicine, 
emergency medicine and paediatrics1.  
 
Bedside use of cardiac-, lung-, and optic nerve sheath diameter ultrasound imaging aids the 
rapid diagnosis of severe and life- threatening pathologies, and effective management. 
During the last decade the development of new digital technology, miniaturisation to 
handheld devices, affordability, and increased availability of equipment, has led to the 
introduction of this skill into everyday practice. In resource poor environments point of 







Preeclampsia (PE) is a multisystem disorder of pregnancy, it is one of the leading causes 
of maternal and neonatal mortality and morbidity worldwide. It is estimated that 10-15% 
of maternal deaths worldwide are caused by this disease and its complications3. The life-
threatening complications of preeclampsia and eclampsia are renal failure, cerebral 
haemorrhage, coagulopathy, cardiac failure, acute respiratory distress syndrome, and liver 
failure3-6. PE also has life-threatening consequences for the developing fetus - intrauterine 
growth restriction, oligohydramnios, preterm delivery, placental abruption, intrauterine 
death. 
 
The features of PE are new onset hypertension and either the presence of end organ damage 
or significant proteinuria. Diagnostic criteria according to the American College of 
Obstetricians and Gynaecologists are the following 7: 
 
Hypertension defined as: 
 New onset systolic blood pressure (SBP) after 20 weeks gestation ≥ 140 mmHg or 
diastolic blood pressure (DBP) ≥ 90 mmHg on two occasions at least 4 hours apart, 
in previously normotensive patients. 
 If SBP is ≥ 160 mmHg or DBP ≥ 110 mmHg, treatment should be initiated within 
minutes. 
AND 
Proteinuria defined as: 
 24 hour urine collection ≥ 0.3 g 
or 
 Protein:creatinine ratio ≥ 0.3 
 Urine dipstick ≥ 1+ (when other methods of quantification are not available). 
OR 
If there is no proteinuria, preeclampsia can be defined as new onset hypertension in 
combination with new onset of any of the following features: 





o Serum creatinine ≥ 97 umol/L, or more than twice baseline in the absence 
of previous renal disease. 
 Thrombocytopenia.  
o Platelet count ≤ 100 × 109/L 
 Liver dysfunction. 
o Transaminase level twice normal upper limit. 
 Pulmonary oedema. 
 Visual disturbance or cerebral impairment. 
 
Preeclampsia with severe features is defined as: 
 
 SBP ≥ 160 mmHg or DBP ≥ 110 mmHg on more than 2 occasions at least 4 hours 
apart, in a parturient on strict bed rest. 
 New onset visual or cerebral disturbances. 
 Pulmonary oedema. 
 Platelet count ≤ 100 × 109/L. 
 Worsening renal dysfunction defined as serum creatinine ≥ 97 umol/L or more than 
twice baseline in the absence of previous renal disease. 
 Impaired liver dysfunction defined as transaminase level twice normal upper limit 
of local laboratory, severe and persistent epigastric or right upper quadrant pain 
non-responsive to conventional analgesics, and no other alternative diagnosis 
possible.  
4.1 Pathophysiology of preeclampsia 
Preeclampsia is caused by abnormal invasion of the spiral arteries by the interstitial and 
extravillous trophoblast8. This leads to decreased uteroplacental blood flow and therefore 
a relative hypoxic environment for the trophoblast8. This problem of hypoperfusion 
worsens as pregnancy progresses and the abnormal vasculature cannot accommodate the 
physiological rise in uteroplacental blood flow essential for fetal development. The 
hypoperfusion, subsequent ischaemia and hypoxia result in the development of 





function. This endothelial cellular dysfunction leads to the characteristic signs and 
symptoms of PE. The endothelial dysfunction results in vasospasm causing multi-organ 
hypoperfusion and systemic hypertension9. 
 
5 Cardiac ultrasound  
Transthoracic echocardiography (TTE) is an easily accessible tool in the diagnosis of 
cardiac dysfunction in pregnancy; the parasternal and four-chamber views are easily 
identified even in the morbidly obese parturients10. Anatomical displacement of the heart 
anteriorly and towards the left further aids the performance of echocardiography in 
pregnant women11. 
  
TTE allows detailed assessment of cardiac structure, systolic and diastolic function. It is 
an essential tool in the guidance of anaesthesia and critical care management in pregnancy. 
It also aids in distinguishing between cardiogenic versus non-cardiogenic pulmonary 
oedema in preeclampsia. TTE can also be used to differentiate between pulmonary oedema 
in the setting of reduced or preserved ejection fraction12. Multiple echocardiographic 
techniques are employed for complete cardiac assessment, Motion Mode, Doppler, tissue 
Doppler Index (TDI), and recently the use of three dimensional imaging and myocardial 
strain assessment with speckle-tracking12-14.  
 
It is imperative to distinguish between a comprehensive TTE examination, focused cardiac 
ultrasound (FoCUS), and limited TTE. A comprehensive TTE examination involves the 
use of specific equipment, assists with diagnosing pathology, and requires a larger 
knowledge base with specialized training15. FoCUS as a screening modality is used to 
answer a specific clinical question, relating to chamber size, volume status, ventricular 
function, and pleural and pericardial effusion. This application does not require detailed 
cardiology knowledge, and a less intensive training period is needed16. However, 
interpretation of the images requires adequate training and is operator-dependent. FoCUS 
does not replace the requirement for a formal diagnostic echocardiography investigation. 






There are multiple guidelines for the use of echocardiography and point of care 
echocardiography15,17-22. Dennis et al described the Rapid Obstetric Screening 
Echocardiography (ROSE) protocol. It has been specifically developed in the obstetrics 
population10 for haemodynamic and diagnostic assessment in the critically ill patient. 
 
ROSE uses the basic parasternal and apical views (subcostal view is not feasible in this 
population) and follows the following main principles10:   
 
 Are the views acceptable and applicable? 
 The test is done at the bedside and on the left of the parturient. 
 This an abbreviated examination.  
 The aim is to diagnose a specific condition and monitor the response to initiated 
therapy (contractility and volume). 
 Right heart function and assessment of size in relation to the left (detection of 
embolism-air, blood, amniotic fluid). 
 Assessment of the fetal heart rate. 
5.1 The cardiovascular pathophysiology of preeclampsia 
TTE has been used extensively in research on preeclampsia, and has aided in identifying 
the underlying pathophysiology13,23,24. Studies have also identified the longer term 
cardiovascular complications of preeclampsia13. 
5.1.1 Pre clinical phase 
In the early onset preeclampsia population, the impairment is more prominent than in the 
late onset group. Early onset preeclampsia has a more severe course than that of late onset 
disease. The initial findings during the course of the disease in the early onset group are 
low cardiac output, high peripheral vascular resistance, contracted intravascular volume 
and decreased venous capacity25,26. In the late onset group these changes are not as well 
delineated. Parturients that develop early or late onset preeclampsia also exhibit abnormal 
left ventricular (LV) remodelling25,27. Most commonly this can be identified as concentric 






Women that will develop early onset preeclampsia have evidence of impaired myocardial 
relaxation and diastolic dysfunction25,27. This relaxation impairment is caused by the 
increased systemic vascular resistance (SVR) higher arterial blood pressure and subsequent 
LV remodelling. With the use of TDI and strain index, the assessment of systolic function 
shows preserved radial function and reduced longitudinal function28. This remodelling and 
dysfunction is similar to changes observed in early essential hypertension in non-pregnant 
patients25,28. These cardiovascular findings support our understanding that preeclampsia is 
not only related to placental abnormalities but also to maternal cardiovascular adaptation 
in response to placental hypoperfusion25,28. 
5.1.2 Clinical phase 
Different disease patterns seen during this phase depend on the severity of the disease, 
treatment employed, pre-existing medical conditions, the presence or absence of labour, 
and fluid administration. LV remodelling patterns are characterised, most commonly by 
concentric hypertrophy12,14,29, however Melchiorre et al also described asymmetrical 
hypertrophy (involving predominantly the anteroseptal portion, with the identification of a 
basal septal bulge). This occurred in patients with severe preeclampsia, who had global 
diastolic dysfunction29. There is a significant increase in LV mass compared to pregnant 
patients without preeclampsia12,14,30. 
 
Global systolic function is usually preserved in patients with preeclampsia as reported by 
Melchiorre et al and Tatapudi et al24,29. Dennis et al found that systolic function was 
increased in patients with PE compared to controls, which was attributed to increased 
inotropy23. The difference in findings in these studies can be attributed to the different 
parameters used for the assessment of systolic function. Speckle tracking, which is a 
relatively new echocardiographic method to assess subtle subclinical changes in 
myocardial strain, demonstrated decreased systolic and diastolic myocardial deformation 
in parturients with PE31. Cardiac magnetic resonance imaging has further demonstrated 
that composition of the myocardial wall in patients with PE differ from healthy controls, 






Global diastolic dysfunction in PE occurs commonly, with left atrial (LA) enlargement, 
most likely due to increased LV filling pressure25. Dennis et al found that 43% of patients 
with untreated severe PE had grade 1 or 2 diastolic dysfunction23. In patients with treated 
severe preeclampsia this incidence was nearly 30%30. Significant pericardial effusion was 
also commonly identified in both treated and untreated patients with PE23,30. 
5.1.3 Long term cardiovascular outcome  
Persistence of diastolic dysfunction, LV hypertrophy and development of essential 
hypertension occur more commonly in patients with early onset disease versus late onset 
disease32. In up to 60% of early onset disease these problems persist beyond the 1 year 
mark. There is a 15 fold increase in relative risk for the development of essential 
hypertension if these problems persist beyond 1 year32. Left ventricular remodelling 
improved significantly at 1 year, though 41 % still had concentric and eccentric 
hypertrophy with concentric remodelling32. This was most likely to occur in patients with 
early onset disease. 
  
There was a significant increase in American Heart Association (AHA) stage B heart 
failure, this occurred most commonly amongst patients that had early onset disease. In the 
normal population above the age of 45 years the prevalence of stage B heart failure is 34 
%; in previously early onset preeclamptics aged 31 years the prevalence is 70%32. 
 
6 Lung ultrasound and the assessment of pulmonary interstitial syndrome 
The use of bedside lung ultrasound has now become standard of care in the critical care 
and emergency environments33-37. Powell et al demonstrated that a fluid bolus in healthy 
parturients prior to spinal anaesthesia lead to endothelial glycocalyx disruption38. 
Pulmonary interstitial syndrome (PIS), which may be a precursor of alveolar oedema, has 
been defined by the presence of multiple B-lines, defined as discrete laser-like vertical 
hyperechoic reverberation artifacts which arise from the pleural line to the bottom of the 
screen, moving as the pleural surfaces slide during respiration39. Three or more B-lines 





is diagnosed in the presence of two or more positive regions per side, which defined a “B-
line pattern”39. In preeclampsia there is an alteration of the endothelial glycocalyx structure 
due to reduced mRNA transcription, and this may lead to an increase propensity to develop 
PIS40. Early identification of pulmonary interstitial oedema may avert the development of 
life-threatening pulmonary oedema, by timely intervention.  
6.1 Lung ultrasound in preeclampsia 
Data in this specific population is scarce, and only two studies could be identified. 
Ambrozic et al. included 21 patients with preeclampsia and 12 healthy controls in their 
study on lung and cardiac ultrasound for haemodynamic monitoring40. Fluid management 
was guided by the findings. Zieleskiewicz et al. included 20 patients with severe 
preeclampsia in their cohort study41, and found that lung ultrasound predicted pulmonary 
interstitial oedema in 25 % of cases, and was associated with raised left ventricular end-
diastolic pressure (LVEDP)40,41. Therefore lung ultrasound could be considered to guide 
the administration of fluid or diuretic therapy.  
 
7 Optic nerve sheath diameter  
7.1 Rationale for measurement 
The optic nerve is covered by the optic nerve sheath. The sheath is an anatomical extension 
of the dura mater and is surrounded by the subarachnoid space. If pressure rises in the 
subarachnoid space the optic nerve sheath will increase in diameter and can therefore be 
used as a noninvasive bedside tool for the estimation of intracranial pressure (ICP)42,43. 
There is a linear correlation between optic nerve sheath diameter (ONSD) and intracranial 
pressure in patients with severe head injury44. The current gold standard for measurement 
of ICP remains invasive transcranial measurement with intraventricular or cerebral 






7.2 Value of correlation 
ONSD measurement during bedside ultrasonography has been directly correlated with 
magnetic resonance imaging (MRI) and computed tomography (CT) measurement for the 
assessment of raised intracranial pressure in children with hydrocephalus and adults with 
meningo-encephalitis46-48. The cost of advanced imaging modalities, availability in 
resource constraint environments, as well as exposure to radiation are all problems in 
evaluation of patients with possible raised intracranial pressure. This is further confounded 
by the fact that transport of these patients is often difficult and critical fetal monitoring may 
not possible during this period. Further the use of CT scan and MRI are not feasible for 
serial assessment of ICP. With the use of bedside ultrasonography the diagnosis of raised 
intracranial pressure can be expedited and complications prevented. 
 
The normal optic nerve sheath diameter measured in different populations of normal non 
pregnant volunteers is 4.12 (4.09-4.15) mm49. Numerous publications have debated the 
ideal cut off value of ONSD that correlates with raised ICP (>20 mmHg). This value also 
differs in various ethnic groups, and an ideal value still needs to be established. A recent 
study by Jeon et al correlated bedside ultrasonography with direct intracranial pressure 
measurement during the placement of an extra ventricular drain catheter in neurosurgical 
patients50. The authors of this paper found that in the Korean population the optimal cut off 
value of ONSD was 5.6 mm with sensitivity 94% and specificity of 87%50. Direct 
correlations with invasive measurement of ICP showed a 95% risk for raised ICP with an 
ONSD measurement of 5.8 mm51. Direct measurement of intracranial pressure with 
opening pressure during lumbar puncture has further demonstrated that with withdrawal of 
cerebrospinal fluid (CSF) the optic nerve sheath decreases in diameter52. 
7.3 Optic nerve sheath diameter in preeclampsia and pregnancy 
In the pregnant population data is limited. A small pilot study performed by Dubost et al 
found that in 25 healthy pregnant patients the average ONSD was 4.5 mm (4.3-4.8)43. In 
this study the ONSD of 26 patients with preeclampsia was evaluated. The mean ONSD in 





of patients with severe PE had an ONSD of >5.8 mm, which was compatible with raised 
ICP.  
 
8 Biomarkers as predictors of disease severity 
8.1 Brain natriuretic peptide 
Brain natriuretic peptide (BNP) is secreted by the cardiac myocytes in response to 
atrial/ventricular wall stretching or ischemia. The serum measurement is used to diagnose 
and assess the severity of heart failure. It has been widely used as a predictor of 
cardiovascular events and mortality53-55. The inclusion of BNP as a predictor of 
cardiovascular risk has been incorporated in the assessment of cardiovascular risk for high 
risk individuals and as one of the mainstay methods of assessment in the recent guidelines 
published by the Canadian Cardiovascular Society56. Measurement of either 32 amino acid 
BNP (active form) or 76 amino acid N-terminal pro-BNP(NT-proBNP) can be made as 
both are cleaved from the prohormone proBNP. It is also now possible to measure BNP 
using a readily available and handheld POC device designed by Abbott in the form of i-
STAT © cartilages.  
 
A systematic review by Afshani et al found57 that PE was associated with higher BNP 
levels compared with controls, these raised levels persisted for up to 6 months. In this 
review multiple studies found an association with diastolic dysfunction, raised SVR and 
decreased cardiac output. However the sensitivity and specificity did not allow the 
prediction of cardiovascular disease severity. The ideal cut-off value in this population still 
remains to be determined.  
8.2 Albumin 
Albumin is a major contributor to oncotic pressure, which opposes hydrostatic forces and 
prevents the development of oedema. Low albumin levels have been linked to the 
development of pulmonary oedema58. In a recent investigation performed by Ortner et al59, 
a comprehensive physicochemical acid/base analysis was performed in pre-eclamptic 





alkalosis and hyperchloraemic acidosis. Overall base excess was similar to that in healthy 
patients. It was concluded that rather than the absolute value of the base excess, the 
magnitude of the offsetting contributors to base deficit could indicate disease severity. 
Hypoalbuminaemia may therefore be a widely available and inexpensive marker of 
pulmonary interstitial oedema in preeclampsia. 
 
9 Conclusion 
This narrative review showed that there is limited literature on POCUS-derived 
abnormalities in women with severe preeclampsia. We therefore aimed to establish the 
prevalence of PIS, cardiac dysfunction, and increased ONSD in late onset severe 
preeclampsia. Our primary aim was to examine the association between PIS/ONSD, and 
maternal serum albumin level. The secondary aims were to explore the association between 
PIS/ONSD and cardiac dysfunction and BNP level. The research thus attempted to 
establish the relative contribution of hypoalbuminaemia and cardiac dysfunction to the life-
threatening complication of pulmonary oedema in PE. The association between POCUS-
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1 Abstract  
Background: 
Pilot studies using point-of-care ultrasound (POCUS) in preeclampsia suggest pulmonary 
interstitial- and cerebral edema, and cardiac dysfunction. In addition, laboratory markers 
of oncotic pressure (albumin) and cardiac dysfunction (brain natriuretic peptide [BNP]) 
may be abnormal, but the clinical application remains unclear. This study investigated the 
prevalence of pulmonary interstitial syndrome (PIS), cardiac dysfunction, and increased 
optic nerve sheath diameter (ONSD) in late onset severe preeclampsia. The primary aim 
was to examine the association between PIS/ONSD, and maternal serum albumin level. 
The secondary aims were to explore their association with cardiac dysfunction and BNP 
level, and the association between POCUS-derived parameters and the development of a 
suspicious or pathological cardiotocograph.  
Methods: 
Ninety-five women were enrolled in this prospective cohort study. At diagnosis, a POCUS 
examination of lungs, heart and ONSD was performed. PIS was defined as a bilateral B-
line pattern on lung US, and diastolic dysfunction was measured following an algorithm 
defined by the American Society of Echocardiography. ONSD > 5.8 mm was interpreted 
as raised intracranial pressure (> 20 mmHg). Serum BNP and albumin levels were also 
measured.  
Results: 
PIS, diastolic-, systolic dysfunction, and raised left ventricular diastolic pressure (LVEDP) 
were present in 23 (24%,) 31 (33%), 9 (10%), and 20 (25%) women respectively. ONSD 
was increased in 27 (28%) women. Thirty-nine women (41%) had zero-, 34 (36%) had 1-, 
and 22 (23%) had ≥ 2 ultrasound abnormalities. No association was found between albumin 
levels and PIS (p = 0.4) or B-line score (p = 0.7). No association was found between serum 
albumin and PIS, ONSD, systolic dysfunction or increased LVEDP. PIS was associated 
with systolic- (p < 0.03) and diastolic dysfunction (p = 0.02), and raised LVEDP (p = 
0.009). The BNP level was associated with PIS, systolic- and diastolic dysfunction 





association between ultrasound abnormalities and the development of a 
suspicious/pathological fetal heart tracing within 48 hours of diagnosis (p=0.07).  
Conclusion: 
Pulmonary interstitial syndrome, diastolic dysfunction and increased ONSD were found to 
be common in severe preeclampsia. Cardiac ultrasound abnormalities may be more useful 
than albumin levels in predicting PIS. The BNP level was associated with cardiac and lung 
ultrasound abnormalities, with high specificity.  
 
Key Points Summary:  
 Question:  
Since data on the prevalence of pulmonary interstitial edema (PIS), increased optic 
nerve sheath diameter (ONSD), and cardiac function as assessed by point of care 
ultrasound (POCUS) in severe late onset preeclampsia are limited, the prevalence of 
these abnormalities were studied, as well as the associations between PIS and ONSD 
and serum albumin level, cardiac dysfunction and serum brain natriuretic peptide 
(BNP).  
 Findings:  
POCUS examination revealed a high prevalence of PIS, diastolic dysfunction, and 
increased ONSD, with no association between PIS or ONSD and serum albumin level, 
but a significant association between PIS and cardiac dysfunction and BNP level.  
 Interpretation:  
In late onset severe preeclampsia, abnormalities of cardiac function may be more 
important than hypoalbuminemia in the generation of PIS, with BNP showing good 
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Preeclampsia is a life-threatening hypertensive disorder involving the heart and vasculature 
and affecting 5-8% of pregnancies1. Predominant causes of maternal morbidity and 
mortality are cerebral complications and cardiorespiratory failure2.  
 
Point of care ultrasound (POCUS) is being used increasingly in preeclampsia for diagnostic 
purposes3. Using lung ultrasound, two recent pilot studies detected pulmonary interstitial 
syndrome (PIS) in 25% of women presenting with severe preeclampsia4,5. Such increases 
in pulmonary interstitial fluid may precede alveolar edema. In both studies, the authors 
concluded that women with PIS should be fluid restricted, but the precipitating factors, 
whether cardiac or non-cardiac, such as decreased oncotic pressure related to 
hypoalbuminemia, remain controversial6.  
 
Another POCUS application is to assess for increased optic nerve sheath diameter (ONSD), 
which has been shown in other clinical disciplines to be associated with raised intracranial 
pressure (ICP)7. In a pilot investigation, ONSD was found to be normal in healthy controls, 
but increased in 5/26 (19%) preeclamptic women8. The clinical application of this finding 
remains unclear. As in PIS, it has been hypothesized that reduced serum albumin level, an 
important determinant of oncotic pressure and biomarker of disease severity9,10, might 
contribute to cerebral edema11.  
 
In a subset of preeclamptic women, signs of diastolic dysfunction and impaired myocardial 
contractility can be demonstrated with transthoracic echocardiography (TTE)12. 
Knowledge of cardiopulmonary function in the individual case is essential to the obstetric 
anesthetist for appropriate hemodynamic and fluid management. As the anesthesia 
provider does not have ready access to a comprehensive TTE study performed by a 
cardiologist, POCUS protocols have been developed and used successfully by non-
cardiologists during recent years13. This implies a defined bedside ultrasound examination 
to identify critical pathophysiologic processes that remain undetected by clinical 






It is further well documented that the serum brain natriuretic peptide (BNP) level, a marker 
of cardiac dysfunction, is increased in preeclampsia14,15. However, there is insufficient data 
to confirm that elevated BNP levels identify those preeclamptic women at risk for 
cardiopulmonary abnormalities16. 
 
Therefore, this study was planned to describe the prevalence of POCUS-derived 
abnormalities in women with late onset severe preeclampsia on hospital admission. The 
primary aim was to examine the association between PIS or ONSD, and maternal serum 
albumin level. The secondary aims were to explore the association between PIS or ONSD, 
and cardiac dysfunction and BNP level. The association between POCUS-derived 







After approval by the institutional Human Research Ethics Committee, and written 
informed consent, women presenting with late onset preeclampsia (>34 weeks gestation) 
with severe features, were enrolled in this prospective observational study. The 
investigation was conducted at the University of Cape Town (UCT), Cape Town, South 
Africa, (#IRB 864/2015), in collaboration with the Medical University of Vienna, Vienna, 
Austria, and the University of Washington, Seattle, USA, (#IRB HSD 50964),  in 
accordance with the Declaration of Helsinki and Good Clinical Practice. This observational 
study was reported using the STROBE guidelines17 and registered under ClinicalTrials.gov 
(NCT 02721771).  
Subjects 
Women diagnosed with late onset severe preeclampsia, admitted to Mowbray Maternity 
Hospital, a regional obstetrics state hospital facility in Cape Town, South Africa, were 
screened for enrollment by the study investigators (E.N. and M.F.) not providing clinical 
care.  
Preeclampsia was defined according to the recommendations of the Royal College of 
Obstetricians and Gynaecologists18, and regarded as severe if systolic blood pressure 
exceeded 160 mmHg and/or the diastolic blood pressure exceeded 110 mmHg on at least 
two separate occasions after admission, and proteinuria on urine dipstick was 3+ or more, 
or if there were other clinical features of severity (severe headaches or visual disturbances, 
renal impairment, impaired liver function tests, and/or thrombocytopenia). Late onset 
disease was defined as diagnosis after 34 weeks’ gestation. 
Following informed consent, maternal ultrasound examination was performed, after 
initiation of the established local treatment protocol of UCT. Seizure prophylaxis was 
administered, consisting of magnesium sulfate administered as a loading dose of 4 g 
intravenously, followed by 1 g hourly intravenously. Preeclamptic women were otherwise 
fluid restricted. Blood pressure was managed according to a standardized protocol, using 
alpha-methyldopa, nifedipine or dihydralazine, and the CTG was interpreted according to 





reassuring feature (early or variable decelerations, fetal basal heart rate 100-119 or 160-
179 beats per minute [bpm], or variability less than 5 bpm for up to 40 minutes) and 2 
normal/reassuring features on CTG defined a suspicious fetal heart tracing. Two or more 
non-reassuring features or 1 or more abnormal features on CTG (late or prolonged [>3min] 
decelerations, fetal basal heart rate < 100 or > 180 bpm, or variability less than 5 bpm for 
greater than 90 minutes) defined a pathological fetal heart tracing, which was considered 
to be an indication for cesarean delivery. The decision to proceed with cesarean delivery 
was made by the obstetrics team, independent of the investigators. Proceeding to caesarean 
section was not delayed by the performance of the ultrasound examination. 
Women in labor or unable to understand the study procedure were not included in the study. 
Women with chronic pulmonary disease, collagen disorders, a history of lithium 
intoxication, chronic renal or hepatic disease, urinary tract infection, chorioamnionitis, 
intrauterine fetal death, a body mass index > 50 kg.m-2, or acute asthma, were not 
considered eligible. 
Ultrasound procedures 
Ultrasound procedures were performed following recommendations of the Society for 
Critical Care Anesthesiologists on performing focused critical care basic ultrasound20. All 
ultrasound studies were performed by one of two trained echocardiography investigators 
(EN and CO) not involved in patient care. A Vivid S6 BT 12 machine with a M4S-RS 1.5-
3.6 MHz cardiac transducer (General Electric Healthcare, Boston, Massachusetts) was used 
for lung and cardiac ultrasound, and a 12L-RS 6.0-13.0 MHz transducer for optic nerve 
ultrasound. Ultrasonography images were stored, converted to Digital Images and 
Communications in Medicine format, and analyzed off-line in a blinded manner. 
Approximately ten percent of the scans were randomly selected for re-evaluation, for 
calculation of intra- and inter-observer variability. 
a) Lung Ultrasound  
Lung ultrasound was performed using the validated Eight-region method21, evaluating two 
anterior regions and two lateral regions in each hemithorax. Hyperechoic horizontal 





Figure 1). PIS was assessed by the presence of multiple B-lines, defined as discrete laser-
like vertical hyperechoic reverberation artifacts which arise from the pleural line to the 
bottom of the screen, moving as the pleural surfaces slide during respiration21 (online 
supplemental Figure 1). Three or more B-lines (any size and any distance apart) in a 
particular region, defined a positive lung region. PIS was diagnosed in the presence of two 
or more positive regions per side, which defined a “B-line pattern”21. The total number of 
B-lines counted in all windows defined the B-line score. Less than two positive regions per 
side defined an “A-line pattern”21. 
b) Cardiac Ultrasound 
Parturients rested in the left lateral position for at least 10 minutes before 
echocardiography. Left ventricular parameters were measured according to the 
recommendations of the American Society of Echocardiography22, using parasternal and 
apical echocardiographic windows. Left ventricular systolic function was measured using 
the Quinones method23, and systolic dysfunction was defined as fractional shortening (FS) 
< 25% (left ventricular internal diameter in diastole – left ventricular internal diameter in 
systole) / (left ventricular internal diameter in diastole). Systolic function was secondarily 
assessed by “eyeball” ejection fraction estimated from the apical four chamber view24, and 
by measuring left ventricular fractional area change (FAC) in the parasternal short axis 
view24.  
 
Left ventricular diastolic function was assessed using pulsed-wave and tissue Doppler 
evaluation of the mitral valve apparatus. Left-ventricular early mitral peak flow velocity 
(E) was measured using pulsed-wave Doppler with sample volume at the tips of the 
opening mitral leaflets, and mitral annular tissue velocity (E´) was measured using the 
tissue Doppler function. Diastolic dysfunction and cardiac filling pressures were defined 
following recommendations available during patient recruitment and published by the 
European Society of Cardiology (ESC) and American Society of Echocardiography 
(ASE)25,26. Following the “Practical Approach to Grade Diastolic Dysfunction”, diastolic 
dysfunction was defined as septal and lateral E´ below 8 and 10 cm/s, respectively25. 





and/or septal and/or lateral E/E´ ratio above 15 and 12, respectively25. Normal LVEDP was 
defined as E/E´ ≤ 8. An average E/E´ ratio between 9 - 13 is considered non-diagnostic, 
and guidelines25-27 recommend additional invasive or non-invasive testing. Following 
ESC-consensus statement26, a concurrent serum BNP > 200 pg/ml is suggestive of 
increased cardiac filling pressures. Consequently, increased LVEDP was further defined 
by a mean E/E´ value of 9-13 in addition to a serum BNP level of > 200 pg/ml. A more 
detailed description of cardiac ultrasound methodology can be found as online 
supplemental material I. 
c) Measurement of optic nerve sheath diameter (ONSD) 
For the purpose of optic nerve sheath diameter measurement, the patient was positioned 
supine, with the head elevated 30 degrees. The entry of the optic nerve into the globe was 
observed by placing the linear transducer superior and lateral to the eye, on the upper 
eyelid. For each optic nerve two measurements were made, one in the transverse plane and 
the other in the sagittal plane. ONSD was calculated by taking the mean of the 4 values (2 
per eye). Increased ICP was defined as a bilateral mean ONSD > 5.8 mm8,28. An illustrative 
example appears in the supplemental Figure 1. 
d) Blood sampling 
Venous blood samples were obtained from the extremity contralateral to the peripheral 
venous access. BNP was measured from one blood specimen immediately after sampling, 
with a designated BNP cartridge on an i-STAT® Analyzer (Abbott Laboratories, Abbott 
Park, IL, USA). Samples of separated plasma were sent to the central hospital laboratory 
services and analyzed for serum albumin, by a fully automated analyzer (Hitachi 917, 
Roche Diagnostics® GmbH, Mannheim, Germany).  
Statistical analysis 
Data was presented as mean and standard deviation for continuous variables, and frequency 
and percentage for categorical variables. For the a priori defined ultrasound outcomes of 
PIS, cardiac systolic dysfunction, diastolic dysfunction, raised left ventricular end diastolic 
pressure (LVEDP), and increased ONSD, the prevalence and 95% confidence intervals 





markers, and between cardiac and pulmonary ultrasound abnormalities, were explored 
using the 2-sample t-test and the Chi-square test, for categorical and continuous variables 
respectively. The association between the presence of ultrasound abnormalities and a 
suspicious or pathological CTG, were explored using a univariate, binomial regression 
model with robust standard errors. For these exploratory analyses, no adjustment was made 
for multiple testing, and results were considered as hypothesis-generating. Intra-observer 
and inter-observer variabilities for lung- (using total B-line score), cardiac- (using left 
ventricular internal diameter in diastole), and optic nerve (using the left optic nerve sheath 
diameter) parameters were evaluated using the Bland-Altman method; results were 
expressed both graphically and quantitatively as mean difference (bias) and 95% limits of 
agreement. 
Sample size calculation 
Available data suggested that the incidences of PIS and increased ONSD detected by 
ultrasound in severe preeclampsia were 24 and 25% respectively8,29. Prior data in critically 
ill patients indicate a mean serum albumin level of 2.8 g/dL (SD 0.7) in patients with 
normal lung water, compared to 2.2 g/dL (SD 0.7) in patients with increased lung water30. 
With the biologically plausible assumption of a similar relationship in preeclampsia, where 
prior data suggests a mean serum albumin level ranging from 2.4 -2.9 g/dl in severe 
disease10, and considering an alpha level of 0.05 and a power of 0.9, a sample size of 80 
women was needed to show a difference of 0.6 g/dL (SD 0.7) in serum albumin level in 
patients with- and without PIS, or with- and without raised ONSD, assuming an unequal 
allocation ratio of 3. No formal sample size calculation was done for the secondary aims, 







Demographic, clinical, and laboratory features 
Of the 201 patients initially screened, 95 patients were enrolled (pulsed wave Doppler 
measurements were incomplete in 15 cases, necessitating the recruitment of 15 additional 
patients to allow for a complete analysis in 80 patients, as per sample size calculation). 
Figure 1 shows the detailed flow diagram and numbers analyzed. Demographic and clinical 
characteristics of the patient cohort are shown in Table 1. In the entire cohort, 56 (59%) 
patients had at least one ultrasound abnormality. Patients with- and without ultrasound 
abnormalities were comparable with respect to demographic characteristics and had similar 
admission hemodynamic findings. With the exception of severe headaches or visual 
disturbances, which were more frequently present in women with ultrasound abnormalities 
(84% vs. 64%, p = 0.03), clinical features of disease severity were observed in similar 
proportion in women with- and without ultrasound abnormalities. Regarding admission 
laboratory findings, patients with ultrasound abnormalities had a higher mean BNP level 
(304.0 vs. 124.3 pg/ml, p = 0.03) and lower albumin level (31.6 vs. 33.4 g/l, p = 0.03) than 
those without ultrasound abnormalities. 
Ultrasound findings 
Table 2 describes the ultrasound findings in the cohort, and Figure 2 describes the 
prevalence of the major ultrasound abnormalities (diastolic and systolic dysfunction, PIS, 
raised LVEDP, and elevated ONSD). The mean lung ultrasound B-line score in the cohort 
was 12.2, with 24% of patients having evidence of PIS. The mean fractional shortening in 
the cohort was 32.5%, and 10% of patients had evidence of systolic dysfunction (FS < 
25%). Thirty-three percent of patients had evidence of diastolic dysfunction, and 25% had 
increased LVEDP. The mean ± SD ONSD was 5.4 +0.5 mm in the overall cohort, with 
28% of patients having ultrasonographic measurements compatible with an increased ICP 







Association between ultrasound abnormalities and laboratory markers 
Associations between ultrasound abnormalities and serum albumin level, and serum BNP 
are presented in Table 3. No association was found between serum albumin and PIS, 
ONSD, systolic dysfunction or increased LVEDP. Admission albumin level was associated 
with diastolic dysfunction (p = 0.04). Admission BNP levels were associated with an 
ultrasound diagnosis of systolic dysfunction (p = 0.0009), diastolic dysfunction (p = 0.003), 
increased LVEDP (p = 0.007) and total B-line score (p = 0.002).  
Cardiopulmonary ultrasound relationships 
Table 4 describes the relationship of PIS with cardiac function in the cohort. With respect 
to markers of systolic cardiac function, patients with PIS had a lower mean fractional 
shortening (29.7% vs. 33.4%, p = 0.03) and mean fractional area change (48.3% vs. 52.9%, 
p = 0.02), than patients without PIS. There was also a higher mean left-ventricular diameter 
in end-systole (3.2 cm vs. 2.9 cm, p<0.001) and higher mean left ventricular area in end-
systole (10.4 cm2 vs. 8.9 cm2, p = 0.01) in patients with PIS, than in those without the 
syndrome. Patients with PIS had a higher prevalence of diastolic dysfunction (52% vs. 
26%, p = 0.02), than those without the condition. The proportion of patients with a raised 
LVEDP was significantly different in those with and without PIS (55% versus 15 %, p = 
0.009). 
Association of ultrasound abnormalities with a suspicious or pathological CTG 
The CTG was normal in 45-, suspicious in 27- and pathological in 21 women. In 2 women 
CTG was not performed prior delivery. There was no association between ultrasound 
abnormalities and the development of a suspicious or pathological CTG (p=0.07). 
For lung, cardiac and optic nerve ultrasound measurements, intra-observer variability 
resulted in a mean difference (bias) of 0.3, -1.4 mm, and -0.2 mm, with respect to B-line 
score, left ventricular end-diastolic internal diameter, and ONSD, respectively. For the 
same lung, cardiac and optic nerve ultrasound measurements, inter-observer variability 
resulted in a bias of 0.6, -1.3 mm, and 0.3 mm respectively. The graphical depiction of the 
limits of agreement of intra- and inter-observer variabilities is presented in the 






Employing several modalities of POCUS examination in women presenting with severe 
clinical features of preeclampsia at > 34 weeks of gestation, we found a high prevalence of 
PIS, diastolic dysfunction and raised ONSD, with acceptable inter- and intra-observer 
variability. The serum albumin level was lower in patients with ultrasound abnormalities, 
but there was no association with PIS or raised ONSD, or with echocardiographic markers 
of systolic dysfunction and raised LVEDP. PIS was associated with several 
echocardiographic abnormalities, including raised LVEDP. BNP was associated with PIS 
and echocardiographic abnormalities. There was no association between ultrasound- and 
CTG abnormalities.  
 
Lung ultrasound has become a standard tool in the diagnosis of pulmonary disorders21. 
Zieleskiewicz et al.29 detected PIS in 5/20 (25 %) women presenting with severe features 
of preeclampsia, and by applying a similar technique, we found a similar proportion of 24 
% in a larger cohort of 95 preeclamptic women. Lung ultrasound is a highly sensitive tool 
to detect accumulation of extravascular fluid early in the course of lung injury31, but it 
cannot differentiate between a cardiac or non-cardiac source of PIS32. Pulmonary-and 
cerebral edema in preeclampsia have several contributing factors. These include colloid 
osmotic pressure33, capillary permeability (increased in the presence of a disrupted 
pulmonary endothelial glycocalyx), and capillary hydrostatic pressure (increased with 
excessive fluid administration and /or cardiac dysfunction, which is further evidenced by 
elevated BNP levels). Serum albumin, which is an important main determinant of colloid 
osmotic pressure, did not correlate with PIS or raised ONSD in our cohort. However, the 
mean serum albumin concentrations > 3.0 g/dl in our cohort are higher than those usually 
reported in early onset disease9,10, where it has been described as a marker of disease 
severity, and may predict pulmonary edema, as well as the requirement for urgent 
delivery9,10.  
 
Using echocardiographic measures as surrogate markers for diastolic dysfunction, 





E´ wave velocity and an increased E/E´ ratio. Performing a cardiac and lung ultrasound in 
21 preeclamptic women and 12 healthy controls, Ambrozic et al.5 measured higher mean 
E/E´ values in women with preeclampsia, but did not find a correlation between number 
of B-lines and raised E/E´ ratio. Using a comparable echocardiographic approach, we could 
confirm an association between diastolic dysfunction and the presence of PIS. In our 
cohort, there was a similar association between PIS and raised LVEDP on ultrasound, to 
that found by Zieleskiewicz et al.29 Further exploratory analysis of our data showed that 
the absence of PIS had a specificity and negative predictive value of 85% for a raised 
LVEDP. 
  
Based on measurements of FS and FAC, systolic function was preserved in most women 
in our cohort, and systolic dysfunction was present in a similar small subset as described 
in other comprehensive TTE investigations in preeclampsia33,34. We found a significant 
association between reduced FS, FAC, raised LVEDP and a B-pattern on lung ultrasound, 
indicating that reduced contractile function and cardiac reserve may increase the risk for 
the development of PIS.  
An additional indication of validity of our cardiac ultrasound findings is the significant 
association found between raised BNP levels and echocardiographic markers of impaired 
systolic and diastolic function. The mean BNP level of 234 pg/ml in our study is 
comparable with the value of 254 pg/ml described in late onset disease by Hamad et al.14 
Post hoc analysis was performed, using a clinically relevant BNP threshold of 200 pg/ml, 
which is reported as the upper range during normal pregnancy and gestational 
hypertension33,34. This showed that elevated BNP was associated with systolic dysfunction 
(sensitivity and specificity 50% and 72%, respectively), diastolic dysfunction (sensitivity 
and specificity 54% and 84%), elevated left-ventricular end-diastolic pressure (sensitivity 
and specificity 57% and 82%), and PIS (sensitivity and specificity 58% and 79%). Overall, 
our results suggest that in late onset disease colloid osmotic pressure may be of lesser 






A reduced serum albumin level may also contribute to cerebral edema in critical illness 
and preeclampsia11,35. Assessing ONSD as a surrogate marker for cerebral edema36, Dubost 
et al. found ONSD to be increased in 5/26 (19%) preeclamptic women8, and measured a 
median ONSD of 5.4 mm in their preeclamptic cohort. Using similar methodology to 
measure ONSD and to define increased ICP, we found a similar mean ONSD of 5.4 mm 
and a prevalence of increased ICP of 28%. No association was observed between increased 
ONSD and any clinical symptom on admission, cardiopulmonary parameter on ultrasound, 
or laboratory biomarker.   
 
Although there was no association between ultrasound- and CTG abnormalities in these 
patients with late onset disease, the clinical importance of POCUS in the identification of 
abnormalities in women with early onset disease (<34 weeks gestation), where expectant 
management is usually attempted, remains to be investigated.  
 
There are some limitations to our study. Firstly, only patients with late onset disease were 
studied. Early onset disease seems to be associated with greater cardiac impairment37, and 
in the setting of expectant management a POCUS examination could be of greater clinical 
importance in the prediction of the progression of disease severity. Secondly, we did not 
include healthy controls in our study. However, a recent lung ultrasound investigation in 
150 healthy parturients at > 36 weeks gestation, found no B-patterns38. Furthermore, no B-
patterns have been identified in previous investigations applying lung ultrasound in control 
cases in preeclampsia studies5,29. With regard to ONSD, Dubost et al. could not detect 
increased ONSD in any healthy control, and they reported a 95%CI of ONSD in healthy 
controls lying at 4.3 – 4.8 mm8, which is significantly below the cut-off point of 5.8 mm 
used in both the study of Dubost and our own. The optimal ONSD cutoff value to define 
increased ICP remains controversial39. Lastly, beyond our pre-specified primary analysis, 
we conducted several additional analyses based on strong biologic plausibility, but without 
correction for multiple testing; thus, we consider the results of our secondary analyses to 






In conclusion, this study revealed a high prevalence of ultrasound abnormalities, with no 
association with serum albumin levels, in women presenting with severe features of late 
onset preeclampsia. Abnormalities of cardiac function were associated with PIS, and may 
be may be more important than hypoalbuminemia in the generation of PIS in late onset 
preeclampsia. BNP is associated with cardiopulmonary ultrasound abnormalities on 
admission. POCUS may serve as a useful adjunct to the clinical examination for the 
obstetric anesthesiologist caring for these complex patients. Further investigations are 
required in patients with early onset preeclampsia, to establish both the prevalence and 
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Figure 1: Flow diagram of patient recruitment  
 






































PIS: Pulmonary interstitial syndrome 
ONSD: Optic nerve sheath diameter  
  
Enrolled 
n = 97 
Screened 
n = 213 
Eligible 
n = 103 
 Declined participation (n = 3) 
 Transfer to other facility (n = 3) 
 
Without PIS (72/95) 
Without raised ONSD (68/95) 
Not eligible: 
 Incorrect diagnosis (n = 13) 
 Early onset disease (n = 22) 
 Twin pregnancy (n = 1) 
 In labor (n = 26) 
 HIV positive (n = 38) 
 Age < 18 yrs old (n = 9) 
 Unable to consent (n = 1) 
With PIS (23/95) 
With raised ONSD (27/95) 
 Withdrew consent (n=1) 
 Labor during ultrasound 
examination (n=1) 
Final Enrollment 





Figure 2: Prevalence of ultrasound abnormalities in woman diagnosed with late onset 




PIS: Pulmonary interstitial syndrome. 
ONSD: Optic nerve sheath diameter. 







Table 1: Patient characteristics, clinical features and laboratory results.  













 (n=95) (n= 39 ) (n= 56)  
     
Clinical 
Characteristics 
     
Age (years) 27 + 6 26 + 6 27 + 6 0.61 
     
Gestation (weeks) 39 + 2.5 39 + 3 39 + 2 0.99 
     
Gravida 2 + 1 2 + 1 2 + 1 0.78 
     
Parity 1 + 1 1 + 1 1 + 1 0.94 
     
Weight (kg) 80 + 18 78 + 17 81 + 18 0.23 
     
Height (cm) 160 + 6 160 + 7 160 + 6 0.73 
     
Body mass index 
(kg/m2) 31.3 + 7.5 30.4 + 7.1 32.0 + 7.8 0.33 
     
Systolic blood 
pressure (mmHg) 165 + 18 163 + 16 167 + 19 0.35 
     
Diastolic blood 
pressure (mmHg) 105 + 12 103 + 10 106 + 14 0.37 
     
Mean arterial 
blood pressure 
(mmHg) 125 + 12 123 + 10 126 + 13 0.27 
     
Heart rate 93 + 17 91 + 17 95 + 17 0.29 
     
Severe Features 
     
Hypertension 72 (76%) 30 (77%) 42 (75%) 0.83 
     
Severe proteinuria 35 (37%) 12 (31%) 23 (41%) 0.31 
     





Headache / visual 
disturbance 72 (76%) 25 (64%) 47 (84%) 0.03 
     
Oliguria 2 (2%) 1 (3%) 1 (2%) 0.8 
     
Impaired liver 
function 1 (1%) 0 (0%) 1 (2%) 0.4 
     
Thrombocytopeni
a 2 (2%) 1 (3%) 1 (2%) 0.8 
     
Number of Severe 
Features 




1 23 (24%) 13 (33%) 10 (18%) 
 
    
2 56 (59%) 22 (56%) 34 (61%) 
    
> 2 16 (17%) 4 (10%) 12 (21%) 
     
Laboratory 
Results 
     
Hb (g/dl) 11.7 + 1.8 11.9 + 1.8 11.7 + 1.9 0.63 
     
Platelet count (x 
109/l) 238 + 79 222 + 64 249 + 88 0.1 
     
Total protein (g/l) 61.8 + 6.0 62.9 + 6.6 61.0 + 5.5 0.16 
     
Creatinine 
(µmol/l) 55.0 + 14.6 53.3 + 11.8 56.1 + 16.2 0.37 
     
Albumin (g/l) 32.3 + 4.1 33.4 + 5.2 31.6 + 2.9 0.03 
     
Brain natriuretic 
peptide (pg/ml) 235 + 346 124 + 78 304 + 425 0.03 
     
Values are mean (+ SD) for continuous variables and frequencies (%) for categorical 
variables. Ultrasound abnormalities** include presence of increased optic nerve sheath 











Preeclamptic Women  
(n = 95) 
  
Optic Nerve Sheath Ultrasound: 
  
Optic nerve sheath diameter (mm) 5.4 + 0.5 
  
Raised intracranial pressure (ONSD > 5.8 mm) 
27 (28 %) 
[95 % CI: 20 % - 39 %] 
  
Lung Ultrasound:  
  
B-line score 12.2 + 8.1 
  
Pleural effusion 4 (4 %) 
  
Pulmonary interstitial syndrome 
 
23 (24 %) 
[95 % CI: 16 % - 34 %] 
  
Cardiac Ultrasound:  
  
Left ventricular area end-diastole (cm2) 19.1 + 3.9 
  
Left ventricular area end-diastolic area (cm2) 9.3 + 2.5 
  
Fractional area change (%) 51.8 + 8.3 
  
Left ventricular internal diameter end-diastole (cm) 4.4 + 0.9 
  
Left ventricular internal diameter end-systole (cm) 3.0 + 0.5 
  




9 (10 %) 
[95 % CI: 4 % - 17 %] 
  
Early mitral peak flow velocity ((E), cm/s) 92.4 + 21.5 
  
Atrial mitral peak flow velocity ((A), cm/s)) 75.0 + 18.1 
  






Mitral inflow deceleration time (sec) 173.5 + 40.4 
  
Septal mitral annular tissue velocity (Septal-E′) 9.3 + 2.2 
  
Lateral mitral annular tissue velocity (Lateral-E′) 11.0 + 2.8 
  
Left atrial diameter (cm) 3.75 + 0.55 
  
Septal E / E′  10.3 + 3.3 
  





31 (33 %) 




(n = 80) 
20 (25 %) 
[95 % CI: 16 % - 36 %] 
  
Values are mean + standard deviation for continuous variables, and counts (percentage) 
for categorical variables.  
Ultrasound abnormalities include raised intracranial pressures, pulmonary interstitial 
syndrome, systolic dysfunction, diastolic dysfunction and raised left ventricular end-
diastolic pressure (LVEDP), and are presented as counts, percentage (%), and 95 % 
confidence intervals [95 % C.I.].  
Incidence ratio of raised LVEDP is based on a denominator of 80 women with complete 







Table 3: Association of ultrasound abnormalities with serum albumin (g/L) and brain 
natriuretic peptide (BNP, pg/ml)) 
   
 Serum Albumin (g/L) BNP (pg/ml) 




   
Positive (n=23) 31.8 (+3.3) 349 (+341) 
Negative (n=72) 32.5 (+4.3) 197 (+342) 
p-value 0.25 0.047 
   
ONSD > 5.8 mm   
   
Positive (n=27) 32.1 (+2.5) 215 (+212) 
Negative (n=68)  32.4 (+4.6) 242 (+385) 
p-value 0.63 0.62 
   
Systolic Dysfunction   
   
Positive (n=9) 31.3 (+3.4) 588 (+800) 
Negative (n=86) 32.5 (+4.2) 192 (+222) 
p-value 0.21 0.0009 
   
Diastolic Dysfunction   
   
Positive (n=31) 31.2 (+3.2) 383 (+533) 
Negative (n=64) 32.9 (+4.4) 156 (+137) 
p-value 0.04 0.003 
   
Increased LVEDP   
   
Positive (n=20) 32.2 (+7.3) 449 (+672) 
Negative (n=60) 32.4 (+3.1) 170 (+183) 
p-value 0.44 0.007 
   
Values are presented as mean and standard deviation (+SD). 
ONSD: optic nerve sheath diameter  





   
 
Table 4: Association of Pulmonary Interstitial Syndrome (PIS) with Cardiac 
Ultrasound Parameters 
 
Variable No PIS PIS  p-value 
 (n=72) (n= 23)  
    
Systolic Function    
    
Left ventricular area end-diastole 
(cm2) 
18.8 + 3.9 
 




    
Left ventricular area end-systole 
(cm2) 
8.9 + 2.4 
 




    
Fractional area change (%) 52.9 + 7.4 48.3 + 9.9 0.02 
    
Left ventricular internal diameter 
end-diastole (cm) 
4.3 + 0.4 
 




    
Left ventricular internal diameter 
end-systole (cm) 
2.9 + 0.4 
 




    
Fractional shortening (%)  33.4 + 7.2 29.7 + 6.3 0.03 
    
Systolic dysfunction 5 (7%) 4 (17%) 0.14 
    
Diastolic Function    
    
Early mitral peak flow velocity 
(E) (cm/s) 92.1 + 21.6  93.3 + 21.8 0.83 
    
Atrial mitral peak flow velocity 
(A) (cm/s) 
74.2 + 18.2 
 




    
E / A ratio 1.2 + 0.3 1.26 + 0.5 0.53 
    
Mitral inflow deceleration time 
(sec) 174.2 + 42.7 171.8 + 34.3 0.82 
    
Left atrial diameter (cm) 3.81 + 0.51 3.78 + 0.41 0.83 





Septal mitral annular tissue 
velocity (Septal-E′) 
9.3 + 2.1 
 




    
Lateral mitral annular tissue 
velocity (Lateral-E′) 
11.1 + 2.7 
 




    
Septal E / E′ 10.1 + 3.1 10.9 + 3.8 0.33 
    
Lateral E / E′ 8.7 + 3.0 9.4 + 3.0 0.4 
    
Diastolic dysfunction  19 (26%) 12 (52%)  0.02 
    
Raised LVEDP* (n=80) 9/60 (15%) 11/20 (55%) 0.009  
    
Values are mean + standard deviation for continuous variables, and counts (percentage) 
for categorical variables.  
Pulmonary interstitial syndrome (PIS) was defined by bilateral B-line pattern in ≥ 2 lung 
regions on pulmonary ultrasound. 
LVEDP ratios are based on a denominator of 80 women with completed E / E′ 
measurements on cardiac ultrasound. 







4 Supplementary material  
Supplementary material 1: Cardiac Methodology 
Point-of-care ultrasound abnormalities in late onset severe preeclampsia: prevalence 
and association with serum albumin and brain natriuretic peptide 
 
Measurement of systolic function 
 
Fractional shortening 
Fractional shortening (FS) was assessed in the parasternal long axis view (PLAX) and 
measured at the level of the tips of the mitral valve 1,2. Left ventricular end diastolic 
diameter (LVEDD) measurements were made at end-diastole, defined by the onset of QRS 
complex on ECG, from inner edge to inner edge of the endo-myocardial border just distal 
to the tips of the open mitral valve leaflets, between interventricular septum and posterior 
wall. The average of three measurements was calculated and taken as FS. Left ventricular 
end systolic (LVESD) measurements were made at the point marking the peak posterior 
deflection of the interventricular septum inner edge to inner edge. An average of three 
measurements was calculated and fractional shortening was estimated using the formula: 
FS (%) = (LVEDD - LVESD) / LVEDD x 100 
FS < 25 % was considered abnormal and defined systolic dysfunction1,2. 
 
Fractional area change  
Fractional area change (FAC) was measured from the parasternal short axis image at the 
mid- papillary level. Left ventricular end-diastolic area (LVEDA [cm
2
]) was calculated by 
freezing the largest image during the recorded cardiac cycle and by then manually tracing 
the endocardial surfaces, excluding papillary muscles3,4. The average of three 
measurements was calculated and defined LVEDA. Left ventricular end-systolic area 
(LVESA [cm2]) was calculated by freezing the smallest image during the recorded cardiac 





The average of three measurements was calculated and defined the LVESA.  
Fractional area change was calculated using the following formula: 
FAC (%) = (LVEDA – LVESA) / LVEDA x 100 
 
Measurement of diastolic function 
Tissue Doppler diastolic velocities  
The tissue Doppler modality was used to measure the velocity of movement of the 
interventricular septum and lateral wall at the level of the mitral valve annulus during 
diastole. From the apical 4-chamber view (A4C), a 5 mm sample volume was positioned 
on the interventricular septum and lateral wall at the junction between the left ventricular 
wall and the fibrous mitral annulus. The septal and lateral E′ wave was the first downward 
(negative) waveform during diastole, of each beat. The peak velocity of the E′ waveform 
was measured during three consecutive beats, and the measurements were averaged. Septal 
or lateral E′ velocity < 8 cm.s-1 or 10 cm.s-1 respectively, are associated with diastolic 
dysfunction in the non-pregnant population, and were considered abnormal5,6.  
In non-pregnant individuals aged 21- 40 years, the normal mean ± SD (range) reference 
values for septal and lateral E′ velocity are 15.5 ± 2.7 (10.1 – 20.9) cm.s-1 and 19.8 ± 2.9 
(14 – 25.6) cm.s-1, respectively5.  
Left atrial diameter  
In the PLAX view, the cursor was directed perpendicular to the long axis of the aorta and 
through the aortic root at the level of the aortic valve cusps. Measurements were made 
when the left atrium was at its maximal size, immediately prior to the opening of the mitral 
valve, from the inner edge of the posterior wall of the aorta to the inner edge of the posterior 
wall of the left atrium, at the end of the T wave of the ECG. The average of three 







Estimation of left ventricular end-diastolic pressure 
Early mitral peak flow velocity (E) was measured using pulsed-wave Doppler modality, 
with the sample volume at the tips of opening mitral leaflets. Increased left ventricular end-
diastolic pressure (LVEDP) was defined by integrating recommendations from a consensus 
statement on the diagnosis of diastolic heart failure, published by the European Society of 
Cardiology6  (ESC), and following recommendations on the evaluation of left ventricular 
diastolic function published by the American Society of Echocardiography (ASE)5. In 
accordance with both statements, an average E/E′ ratio ≤ 8 identifies patients with normal 
left ventricular filling pressures, whereas an average ratio of E/E′≥ 13, and/or septal 
E/E′ratio ≥ 12, and/or lateral E/E′ratio ≥ 15, respectively, indicates increased left 
ventricular pressures5-7. When average ratios are between 9 and 13, E/E′ ratios alone are 
non-diagnostic, and guidelines5,6,8 recommend additional invasive or noninvasive testing. 
Following an ESC-consensus statement6, a concurrent serum BNP > 200 pg/ml is 
suggestive of increased cardiac filling pressures. Consequently, increased LVEDP was 
further defined by average E/E′ of 9-13 with a concurrent serum BNP level of  > 200 pg/ml 
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Supplemental Figure 1: Examples of lung and optic nerve ultrasound findings in a 





A: A-line pattern on lung ultrasound image indicating normal fluid content in lung 
interstitium. 
B: Multiple B-lines on lung ultrasound image indicating increased fluid content in lung 
interstitium. 
C: Measurement of optic nerve sheath diameter (ONSD) using ocular ultrasonography. In 











Diagnostic algorithm in the estimation of left ventricular end diastolic pressure (LVEDP) 
in patients with normal or reduced ejection fraction. Adapted from consensus statement 
on diagnosis of diastolic heart failure published by the European Society of Cardiology 
2007. 
  
Estimation of Left Ventricular End Diastolic Filling Pressures 
(LVEDP) 
E/Eʹ 
E/E′ ≤  8 




Av. E/Eʹ 9-13 
BNP < 200 pg/ml 
Normal 
LVEDP 
BNP ≥ 200 pg/ml 
LVEDP é 
Sept. E/Eʹ ≥ 15 
or  
Lat. E/Eʹ ≥ 12 
or 






Supplemental Figure 3: Intra-observer and inter-observer variabilities  
 
 
Intra-observer and inter-observer variabilities for lung- (using total B-line score), cardiac- 
(using left ventricular internal diameter in diastole), and optic nerve (using the left optic 
nerve sheath diameter) parameters evaluated using the Bland-Altman method; results are 











Lung (total B-line score): 
 
 








Optic nerve sheath diameter (ONSD): 
 
 


































Acid-base disturbances and ultrasound markers as biological predictors 
of maternal and fetal outcomes in severe late onset preeclampsia 
 
Principal Investigators:  Professor RA Dyer 
Co-investigators:   
Prof JL Swanevelder, Dr. E Neethling, M Flint, PhD, Prof CJ Lombard, Dr S Allie, Prof S 
Fawcus 
International Collaborators:  
Dr. C Ortner (Vienna Medical University, Vienna, Austria) 
Dr V Krishnamoorthy (University of Washington, Seattle USA) 
 
1. Purpose of the study 
We are asking for you to be in this study because you are an otherwise healthy pregnant 
woman admitted to Mowbray Maternity Hospital labour and delivery unit, and you now 
have a diagnosis of “pre-eclampsia”, a disease with high blood pressure in pregnancy.  We 
want to see how results of a type of blood test and of ultrasound examinations of your chest 
and eyes compare to the outcome of your delivery.  The blood test looks at so-called acid-
base levels in the blood that may be off-balance in pre-eclamptic patients. The ultrasound 
examination is similar to examinations you might have had during your pregnancy, where 
pictures of your baby where taken with a device called ultrasound machine. An ultrasound 
machine makes sound that you or your baby do not hear or feel to make a picture. This 
“ultrasound” has also no known side effects.  In a similar way, we are now making pictures 
of your heart, lung and eye. The pictures of the heart and lung will tell us if there is risk for 
too much water in your lungs. The picture of your eye will tell us if there is risk for brain 
swelling. This information is very important to the anaesthetist and eventually for the 






2. Study procedures 
If you choose to be in this study, your participation in the study will take place during your 
stay in the hospital before delivery. The following research procedures will take place in 
addition to your standard clinical procedures: 
Collection of blood from the vein:  
We will collect a small amount of blood from you one time for this study. For standard 
clinical care, blood will also be collected from your vein. If possible, we will try to collect 
extra blood from the clinical draws. With the blood draw we will collect 2-3 teaspoons of 
blood, which will take less than 3 minutes to complete. This is necessary for research 
purposes, as some information cannot be obtained from the routine blood draw (detailed 
acid-base status). 
Ultrasound examination of your heart, lung and eye nerve: 
For the study purpose we will perform and ultrasound examination of your heart, lungs and 
eye within 24 hours of your admission. Ultrasound is a non-invasive method to make 
images of your heart, lung and eye nerve. The ultrasound examination of your eye can give 
us important information about the pressure behind your eye. For that purpose ultrasound 
gel will be applied on an ultrasound transducer that will be gently positioned on your chest 
and eye lids. The duration of the ultrasound examination on your chest will take 10-15 
minutes, the examination of your eye will take 5 minutes. So in total the ultrasound 
examinations will take approximately 15-20 minutes. 
Collection of data from the medical record: We will collect information about you and your 
newborn baby from the Mowbray Maternity Hospital record. We will collect information 
about your pregnancy, delivery, and medications from your health history until one-day 
post partum. We will collect information about your baby such as birth weight, APGAR 
score, and overall health.  
3. What are the possible benefits? 
 
There are no benefits associated with taking part in this study.  
 
4. What are the possible risks? 
 
The risk of the taking of a venous blood sample is very low. Besides some minor discomfort 
during ultrasound examination, the ultrasound examination is safe and there is 
no/minimum risk to you and your baby. 
Main risk of the study would be a delay in your treatment. Our study procedures will only 
be performed after your admission has been completed and your clinical care has been 






5. What if Something Goes Wrong? 
 
This research study is covered by an insurance policy taken out by the University of Cape 
Town if you suffer a bodily injury because you are taking part in the study.  
The insurer will pay for all reasonable medical costs required to treat your bodily injury, 
according to the SA Good Clinical Practice Guidelines 2006 (or latest version), which are 
based on the Association of the British Pharmaceutical Industry Guidelines. The insurer 
will pay without you having to prove that the research was responsible for your bodily 
injury. You may ask the study doctor for a copy of these guidelines. 
The insurer will not pay for harm if, during the study, you:  
 Use medicines or other substances that are not allowed 
 Do not follow the study doctor’s instructions 
 Do not tell the study doctor that you have a bad side effect from the study medicine 
 Do not take reasonable care of yourself and your study medicine 
If you are harmed and the insurer pays for the necessary medical costs, usually you will be 
asked to accept that insurance payment as full settlement of the claim for medical costs. 
However, accepting this offer of insurance cover does not mean you give up your right to 
make a separate claim for other losses based on negligence, in a South African court.  
It is important to follow the study doctor’s instructions and to report straightaway if you 
have a side effect from the study medicine. 
 
6. Do I have to take part in this research project? 
 
Participation in any research project is voluntary. If you do not wish to take part, you do 
not have to. If you choose to not participate, this will not affect your treatment, care or 
relationship with this hospital. If you decide to take part and later change your mind, you 
are free to withdraw from the project at a later stage.  
 
7. How will I be informed of the final results of this research project? 
 
If you desire, you can be sent the results of this research in the form of a summary document 
or publication arising from the research. 
 
8. What will happen to information about me? 
 
We will record health information about you and your baby that will include your age, gender, weight, height, 
blood pressure, pulse rate and a history of existing disease. We will also record how far along your pregnancy 






This is information that is usually routinely recorded as part of your pregnancy care. 
You will receive a code number and all information will be stored anonymously in a secured area in the 
Department of Anaesthesia using only this code number.   
The list that matches your name with the code number will be kept in a locked file in the Department of 
Anaesthesia.  
 
On completion of this study the data will be presented for review by the University of Cape 
Town and also for possible publication in a medical journal.  In the event of any publication 
or presentation resulting from the research, no personally identifiable information will be 
shared. Data will only be shared with the international collaborators as mentioned on this 
protocol (Dr. C Ortner, Dr V Krishanmoorthy) and only for the purpose of data analysis. 
We will keep your participation in this research study confidential to the extent permitted 
by law. In accordance with regulatory guidelines, the information collected in this research 
project will be kept for at least 5 years.  
However, it is possible that other people may become aware of your participation in this study. For example, 
the following people/groups may inspect and copy records pertaining to this research in order to ensure that 
the research complies with ethical and clinical requirements.  
  
 Human Research Ethics Committee 
E 52, Room 24, Old Main Building, Groote Schuur Hospital, Observatory 
Telephone:   021 406 6338 
9. Can I access research information kept about me? 
 
In accordance with relevant laws, you have the right to access the information collected 
and stored by the researchers about you.  Please contact Professor RA Dyer, (D23 
Department of Anaesthesia, telephone 0214045142) if you would like to access your 
information or have further study related questions.  
 
10. Can I withdraw from the study? 
 
Participants may withdraw from the study at any time, without affecting their further 
management. 
 
11. Is this research project approved? 
 
The ethical aspects of this research project have been approved by the Human Research 
Ethics Committee of the University of Cape Town. If you want any information regarding 
your rights as a research participant, or complaints regarding this research study, you may 
contact Professor Marc Blockman at the University of Cape Town Faculty of Health 
Sciences  Human Research Ethics Committee which is an independent Committee 








Your signature below means that you have received and understood the information regarding this study, have 
asked the questions you currently have about the research and those questions have been answered. You will 
receive a copy of the signed and dated form to keep for future reference.  
 
 
By signing below, you indicate that you give permission to take part in this research.  
 
     
______________________________         _________ ______ ______________ 




______________________________        _________              ______ ______________ 
Signature of witness 1                                    Date  Printed Name 
 
     
 
 
Person Explaining the Research: Your signature below means that you have explained the research to the 
participant/participant representative and have answered any questions he/she has about the research. 
 
 
______________________________      _________        ________________ 




 Interpreter (where applicable) 
 
 
____________________ ________           ____________________ 






Appendix C: STROBE Checklist 
 
STROBE Statement—Checklist of items that should be included in reports of cohort 
studies 
Please find below how and where in the manuscript each point of the Strobe Statement 
checklist is addressed by the authors in red and italics. 
 Item 
No Recommendation 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title 
or the abstract  
This is mentioned in the abstract 
(b) Provide in the abstract an informative and balanced summary of 
what was done and what was found 
Done 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation 
being reported 
Background and rationale explained and reported in the introduction 
Objectives 3 State specific objectives, including any prespecified hypotheses 
Objectives with primary and secondary aims are clearly stated in last 
paragraph of the Introduction 
Methods 
Study design 4 Present key elements of study design early in the paper 
Stated in 1st paragraph Methods section 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Figure 1 (patient flow chart) and 2nd paragraph Methods section 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up 
2nd paragraph Methods section (under Subjects) 
(b) For matched studies, give matching criteria and number of exposed 
and unexposed 
not applicable 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
Diagnostic criteria: methods page 6, line 16-22 
Defined outcomes: statistical analysis section page 11, line 1-3 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability of 





Ultrasound procedures and laboratory measurements are explained in 
the methods section (page 8-10) and in the supplemental digital 
content submitted with the manuscript. 
Bias 9 Describe any efforts to address potential sources of bias 
In order to address measurement bias, intra- and inter-observer 
reliability were tested (methods page 11, line 11-15) 
Selection bias addressed through meticulous documentation of 
participant disposition presented in patient flow chart 
Study size 10 Explain how the study size was arrived at 
Sample size calculation: page 11 final paragraph / page 12 1st 
paragraph 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses.  
Statistical analysis: page 11 
If applicable, describe which groupings were chosen and why 
not applicable . 
 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
Done, page 10-12 
(b) Describe any methods used to examine subgroups and interactions 
Inferential analysis was performed by t-test, Chi-squared test, and 
univariable binomial regression. No subgroup analysis was 
performed. 
(c) Explain how missing data were addressed 
Missing data was addressed by increasing number of subjects 
enrolled, to ensure 80 complete sets of data, as per sample size 
calculation 
(d) If applicable, explain how loss to follow-up was addressed 
No patient was lost to follow-up 
(e) Describe any sensitivity analyses 
No sensitivity analysis was performed. 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, 
included in the study, completing follow-up, and analysed 
Presented in Figure 1: patient flow chart 
(b) Give reasons for non-participation at each stage 
Presented in Figure 1: patient flow chart 
(c) Consider use of a flow diagram 
Done (Figure 1) 
Descriptive data 14* (a) Give characteristics of study participants (e.g. demographic, 






Presented in Table 1 and Table 2 
(b) Indicate number of participants with missing data for each variable 
of interest 
In 15 patients, PW doppler imaging was incomplete; please see 
comment in the first paragraph of the Results section 
(c) Summarise follow-up time (eg, average and total amount) 
Participants were followed up until delivery (maximum 48 hrs post 
enrollment) 
Outcome data 15* Report numbers of outcome events or summary measures over time 
Presented in Table 1 -4  
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make 
clear which confounders were adjusted for and why they were 
included 
For the a priori defined outcomes the prevalence and 95% confidence 
intervals were calculated. (Results) 
(b) Report category boundaries when continuous variables were 
categorized 
Done 
(c) If relevant, consider translating estimates of relative risk into 
absolute risk for a meaningful time period 
not applicable  
Other analyses 17 Report other analyses done—e.g. analyses of subgroups and 
interactions, and sensitivity analyses 
Intra-observer and inter-observer variabilities for ultrasound 
parameters were evaluated using the Bland-Altman method and 
expressed both graphically and quantitatively as mean difference (bias) 
and 95% limits of agreement (page 11) 
Discussion 
Key results 18 Summarise key results with reference to study objectives 
Stated (1st paragraph of discussion section) 
Limitations 19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and magnitude of 
any potential bias 
Limitations are discussed in detail in the penultimate paragraph of the 
discussion  
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and 
other relevant evidence 
Done 





Done by, inter alia, comparing and confirming findings to those in 
comparable studies 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present 
study and, if applicable, for the original study on which the present 
article is based 
First author received institutional funding, as stated on title page. 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in 
conjunction with this article (freely available on the Web sites of PLoS Medicine at 
http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at 










Appendix D: Anesthesia & Analgesia- Instructions to authors 
 
Available online from: http://edmgr.ovid.com/aa/accounts/ifauth.htm 
We greatly appreciate your interest in submitting your manuscript to Anesthesia & 
Analgesia or A&A Practice (formerly, A&A Case Reports). Our goal is to provide authors 
with a thorough yet timely review of their submissions. All decisions should be 
completed within 6 weeks, except for Review Articles and Special Articles, which may 
take up to 8 weeks. Authors will be updated as to the status of their manuscript and 
notified if delays occur. 
Notice: The Instructions for Authors for Anesthesia & Analgesia and A&A Practice 
(formerly, A&A Case Reports) have been further revised. New submissions should be 
prepared according to the Instructions that follow. Failure to do so may result in your 
submission being returned without review. 
This now current Version 1.3 of the Instructions for Authors replaces the earlier 
Version 1.2. 
In an effort to further promote the existing expanded scope of A&A Case Reports—
specifically, to publish content of practical appeal to a wide audience—the name of 
this journal will become A&A Practice starting in January 2018. 
Additionally, as of January 1, 2018, all Echo Rounds and Echo Didactics articles 
will be published in A&A Practice. 
A&A Practice will remain editorially aligned and operationally integrated yet 
distinct from Anesthesia & Analgesia. 
Mission and Scope 
Anesthesia & Analgesia exists for the benefit of patients under the care of health care 
professionals engaged in the disciplines broadly related to anesthesiology, perioperative 
medicine, critical care medicine, and pain medicine. The Journal furthers the care of these 
patients by reporting the fundamental advances in the science of these clinical disciplines 
and by documenting the clinical, laboratory, and administrative advances that guide 
therapy. Anesthesia & Analgesia seeks a balance between definitive clinical and 
management investigations and outstanding basic scientific reports. The Journal 
welcomes original manuscripts containing rigorous design and analysis, even if unusual 
in their approach. 
Authors are encouraged to read this editorial, which describes some of the previous 
changes to the editorial philosophy of Anesthesia & Analgesia: Pittet JF, Vetter TR. 
Continuing the Terra Firma and Establishing a New EQUATOR for Anesthesia & 





Authors are strongly encouraged to adhere to the fundamentals of English grammar, 
syntax, punctuation, and composition. If a paper is poorly written and thus difficult to 
understand, it will likely not receive as favorable a review, despite presenting strong 
science and/or novel information. If indicated, please consider using a Language Editing 
Service (see below) to address this issue before your initial submission. 
Anesthesia & Analgesia and A&A Practice Instructions for Authors 
Anesthesia & Analgesia and A&A Practice have specific Instructions for Authors for 
submitting articles, which are found below. We strongly encourage all authors to read 
these instructions completely and carefully, and to prepare their manuscripts in 
accordance with these instructions. 
Articles that are not submitted in accordance with our instructions may be returned 
for revision prior to peer-review or rejected outright. 
Brevity is crucial for a well-written and effective scholarly article. 
Particular attention should thus be paid to the listed word count, reference count, 
and table/figure limits for each article type, both for an initial submission and any 
subsequent revisions. 
The word count, reference count, and table/figure limits will be strictly enforced, 
resulting in a manuscript being returned to the author(s) for revision prior to any 
initial or a subsequent peer-review. 
Occasionally, authors will be asked by the Journal Editorial Board to resubmit their work 
as a different article type. If so, this subsequent manuscript will be handled as an entirely 
new submission, with a corresponding new assigned manuscript number. 
Any changes (additions or deletions) of authors will need to be justified and clearly 
communicated. See below, Section 8.A. Role of Authors and Contributors. 
Questions? 
If you have a question specifically for the Editor-in-Chief, Dr. Jean-Francois Pittet, 
please email him at jpittet@iars.org, or contact the Deputy Editor-in-Chief, Dr. Thomas 
Vetter at thomas.vetter@austin.utexas.edu 
If you have questions about these submission instructions, or the Journal peer review 
process in general, please contact the Editorial Office via editor@anesthesia-
analgesia.org 
Manuscripts may only be submitted via the Editorial Manager online submission 





If you are new to our journal, our Visual User Guide for Authors will help you step-by-
step to create an author account and to submit your new manuscript via Editorial 
Manager. 
If you are submitting a revised manuscript, our User Guide for Revisions will help you 
step-by-step to submit your revised manuscript via Editorial Manager. 
Download a PDF version of the full Instructions for Authors of Anesthesia & Analgesia 
and A&A Practice 
INSTRUCTIONS FOR AUTHORS 
Section 1A: Anesthesia & Analgesia Article Types 
Section 1B: A&A Practice Article Topics 
Except were specifically noted, instructions in the following Sections are the same 
for both Anesthesia & Analgesia and A&A Practice 
Section 2: Articles at a Glance 
Section 3: Standardized Study Reporting Requirements 
Section 4: Standards for Statistical Methods and Statistical Reporting 
Section 5: Digital Copyright Transfer Agreement 
Section 6: Open Access Option for Publication 
Section 7: Manuscript Preparation Requirements 
Section 8: Editorial, Ethical and Legal Requirements 
Section 9: Common Reasons Your Submission is Returned Without Review 
SECTION 1A: ANESTHESIA & ANALGESIA ARTICLE TYPES (Back to 
Contents) 
Original Clinical, Health Services or Education Research Report 
Original Laboratory Research Report 
Brief Report 





Systematic Review Articles 
Meta-Analysis 
Editorial 




Letter to the Editor 
Book and Multimedia Reviews 
Meeting Report 
SECTION 1B: A&A PRACTICE ARTICLE TOPICS (Back to Contents) 
In an effort to further promote the existing expanded scope of A&A Case Reports—
specifically, to publish content of practical appeal to a wide audience—the name of 
this journal will become A&A Practice starting in January 2018. 
The scope and content of A&A Practice is intentionally broad. A&A Practice publishes 
short yet informative, peer-reviewed articles that simply describe (a) the unique clinical 
characteristics and/or perioperative, critical care, acute pain-related, or chronic pain-
related clinical care of one to three patients; (b) an important teaching point or novel 
educational tool; or especially (c) an innovative solution to a perioperative, pain, patient 
safety, quality and performance improvement, or global health management issue. 
Additionally, as of January 1, 2018, all Echo Rounds and Echo Didactics articles 
will be published in A&A Practice. 
Data collection and analyses are neither expected nor encouraged for an A&A 
Practice submission. 
Submissions to A&A Practice can form the basis for a subsequent, more extensive proof-
of-concept study or formal research study that is submitted to Anesthesia & Analgesia. 






Please note that the previous requirement for conventional written patient consent 
for case reports, as described in Nussmeier N, Saidman LJ, Shafer S. A & A Case 
Reports: A Progress Report and an Update on Requirements for Patient Consent. AA 
Case Rep. 2014 Dec 1;3(11):141, has been eliminated for submissions from countries 
like the United States where conventional written patient consent is not required. 
Nevertheless, case reports for publication by Anesthesia & Analgesia originating from the 
United States must be prepared in accordance with the requirements of HIPAA privacy 
regulations (See below Section 7.D. A&A Practice Compliance with HIPAA Privacy 
Regulations). 
However, regulations outside the United States regarding case reports or case series, 
including a requirement to obtain written patient consent, must be followed. 
A&A Practice 
DESCRIPTIONS OF SPECIFIC ARTICLE TYPES 
Anesthesia & Analgesia 
Original Clinical, Health Services, or Educational Research Report (Back to Top) 
 An Original Clinical, Health Services, or Educational Research Report describes 
an investigation that focuses on the clinical practice of anesthesiology, 
perioperative medicine, critical care medicine, or pain medicine. 
 Original Clinical, Health Services, or Educational Research Reports span the 
spectrum of patient-reported outcomes, clinical effectiveness, quality and 
performance improvement, patient safety, health services delivery, dissemination 
and implementation science, health policy, healthcare economics, population 
health, and education. 
 An Original Clinical, Health Services, or Education Research Report includes a 
Title Page and structured Abstract of no more than 400 words. 
 A “Key Points” summary is also provided, which describes the Question, 
Findings, and Meaning, each composed of one sentence. 
 These Reports are divided into four sections: Introduction, Methods, Results, and 
Discussion. 
 The Introduction section should be focused and contain no more than 400 words. 
The Introduction succinctly describes, in a series of short paragraphs, the 
significance of the topic, pertinent background, rationale for the study, a 
priori study aims or objectives, and primary study hypothesis, and if appropriate, 
secondary study hypothesis. 
 The Discussion section should also be focused and contain no more than 1,000 
words. The Discussion succinctly interprets the primary findings of the study and 
how they relate to previous published findings. The limitations of the present 






 An Original Clinical, Health Services, or Education Research Report ranges in 
total length from 1,500 to 4,000 words (not counting the Abstract and 
references), with no more than 30-40 references and 4-6 tables and/or figures. 
Online supplemental material can be provided when appropriate. 
 Study Reporting Requirement (EQUATOR) 
 Instructions for Manuscript preparation 
 Instructions for Figure preparation 
 Instructions for Table preparation 
 Instructions for Supplemental Material 
Original Laboratory Research Report (Back to Top) 
 An Original Laboratory Research Report describes an investigation that 
focuses on an aspect of basic science related to anesthesiology, perioperative 
medicine, critical care medicine, or pain medicine. 
 Original Laboratory Research Reports span the spectrum of cell biology, 
immunology, neurobiology, biochemistry, pharmacology, microbiology, and 
genetics. 
 An Original Laboratory Research Report includes a Title Page and structured 
Abstract of no more than 400 words. 
 A “Key Points” summary is also provided, which describes the Question, 
Findings, and Meaning, each composed of one sentence. 
 These Reports are divided into four sections: Introduction, Methods, Results, and 
Discussion. 
 The Introduction section should be focused and contain no more than 400 words. 
The Introduction succinctly describes, in a series of short paragraphs, the 
significance of the topic, pertinent background, rationale for the study, a 
priori study aims or objectives, and primary study hypothesis, and if appropriate, 
secondary study hypothesis. 
 The Discussion section should also be focused and contain no more than 1,000 
words. The Discussion succinctly interprets the primary findings of the study and 
how they relate to previous published findings. The limitations of the present 
study are clearly stated. If applicable, future, related research opportunities are 
briefly proposed. 
 An Original Laboratory Research Report ranges in total length from 1,500 to 
4,000 words (not counting the Abstract and references), with no more than 30-40 
references and 4-6 tables and/or figures. Online supplemental material can be 
provided when appropriate. 
 Study Reporting Requirement (EQUATOR) 
 Instructions for Manuscript preparation 
 Instructions for Figure preparation 
 Instructions for Table preparation 
 Instructions for Supplemental Material 





 A Brief Report describes a clinical or laboratory investigation that does not 
require the breadth of experimentation or documentation expected of an Original 
Research Report. 
 A Brief Report typically involves the analysis of either retrospective or 
preliminary data, thus forming the basis for a subsequent more extensive 
investigation. 
 A Brief Report can also be technical in nature, describing the initial use of a new 
instrumentation or analytic technique. 
 A Brief Report that presents data typically has a smaller sample size than an 
Original Research Report. 
 A Brief Report includes a Title Page and an unstructured Abstract with no more 
than 100 words. Brief Reports contain an Introduction, Methods, Results, and a 
very brief (no more than 1 paragraph long) Discussion. 
 A Brief Report contains no more than 1500 words (not counting the Abstract and 
references), with no more than 15 references and 1 table and/or 1 figure. 
 Study Reporting Requirement (EQUATOR) 
 Instructions for Manuscript preparation 
 Instructions for Figure preparation 
 Instructions for Table preparation 
 Instructions for Supplemental Material 
Narrative and Systematic Review Articles (Back to Top) 
 A Narrative Review Article or Systematic Review Article synthesizes 
previously published material into an integrated presentation of the current 
understanding of a topic. 
 A Narrative Review can be either focused or comprehensive, based on its topic 
and scope. 
 A Narrative Review Article should describe aspects of a topic about which 
scientific and evidence-based consensus exists, as well as aspects that remain 
controversial and are thus topics for ongoing and future research. 
 A duly noted and entitled Consensus Practice Guideline is considered a specific 
type of a focused Narrative Review. 
 A duly noted and entitled Statistical Grand Rounds is another specific type of 
a focused Narrative Review of the conventional or novel application of 
contemporary quantitative sciences (i.e., statistics, epidemiology, or database 
management) to issues of concern to anesthesia, critical care or pain researchers. 
Here the inclusion of programing code and/or illustrative datasets as online 
supplemental material is encouraged. 
 For a Systematic Review, a formal strategy to search and to critically evaluate the 
medical literature should be applied and well-described. Such explicit methods 
are used in a Systematic Review to minimize bias in its content and findings. 
 All Review Articles include a Title Page and an unstructured Abstract with no 
more than 400 words. 





 The Discussion section should also be focused and contain no more than 1,000 
words. 
 A Review Article ranges in total length from 1,500 to 5,000 words (not counting 
the Abstract and references), with up to 150 references and 4-6 tables and/or 
figures. Online supplemental material can be provided when appropriate. 
 Exceptions to these word count, reference count, and table/figure limits may be 
granted at the discretion of the Journal Editorial Board for a Consensus Practice 
Guideline manuscript. 
 Study Reporting Requirement (EQUATOR) 
 Instructions for Manuscript preparation 
 Instructions for Figure preparation 
 Instructions for Table preparation 
 Instructions for Supplemental Material 
Meta-Analysis (Back to Top) 
o A Meta-Analysis uses analytic techniques to combine the quantitative 
results from existing individual studies, which are initially identified via 
a Systematic Review, thereby (a) allowing for a more precise estimate of 
the magnitude of benefit or harm of an intervention and/or (b) increasing 
the applicability of the results to a broader range of patients. 
o A Meta-Analysis should not be written and submitted as a Systematic 
Review Article but as a separate submission type. 
o A Meta-Analysis includes a Title Page and structured Abstract of no more 
than 400 words. 
o A “Key Points” summary is also provided, which describes the Question, 
Findings, and Meaning, each composed of one sentence 
o These manuscripts are divided into four sections: Introduction, Methods, 
Results, and Discussion. 
o The Introduction section should be focused and contain no more than 400 
words. 
o The Discussion section should also be focused and contain no more 
than 1,000 words. 
o A Meta-Analysis ranges in total length from 1,500 to 5,000 words (not 
counting the Abstract and references), with no more 
than 150 references and 4-6 tables and/or figures. Online supplemental 
material can be provided when appropriate. 
o Study Reporting Requirement (EQUATOR) 
o Instructions for Manuscript preparation 
o Instructions for Figure preparation 
o Instructions for Table preparation 
o Instructions for Supplemental Material 
Editorial (Back to Top) 





o An Editorial either (a) provides an editorial perspective on an article 
published in the Journal or (b) expresses the general policies or opinions 
of the Journal Editorial Board. If an Editorial is intended to provide an 
expert perspective on an article or topic published in the Journal, it is 
typically solicited from reviewer(s) who provided unusually thoughtful 
insight during the peer-review process, and which the Editors believe 
should be shared with the Journal readership. 
o An Editorial includes a Title but not an Abstract. 
o An Editorial contains no more than 2000 words (not counting the 
references), with no more than 15 references and occasionally 1 table 
and/or 1 figure. 
o Instructions for Manuscript preparation 
o Instructions for Figure preparation 
o Instructions for Table preparation 
o Instructions for Supplemental Material 
The Open Mind (Back to Top) 
o The Open Mind is a unique forum for thoughtful, scholarly, and preferably 
well-referenced perspectives. The Open Mind is intended to stimulate 
lively yet civil discussion. It is a forum for (a) challenging myths or 
dogma and/or (b) proposing new approaches or solutions to an important 
issue facing the anesthesiology community. 
o Submissions to The Open Mind include a Title Page but not an Abstract. 
o An Open Mind article ranges in total length from 1,500 to 3,000 
words (not counting the references), with up to 20 references and 2-3 
tables and/or figures. 
o Instructions for Manuscript preparation 
o Instructions for Figure preparation 
o Instructions for Table preparation 
o Instructions for Supplemental Material 
Special Article (Back to Top) 
o A Special Article is a manuscript that does not fit in any of the other 
article types. They are typically invited by the Editorial Board to examine 
a particular topic. 
o Occasionally, authors produce a publishable scholarly text that does not fit 
one of the other article types. After first communicating directly with the 
Journal’s Editor-in-Chief, these may be submitted as a Special Article. 
o All Special Articles include a Title Page and an unstructured Abstract with 
no more than 400 words. 
o A Special Article ranges in total length from 1,000 to 5,000 words (not 
counting the Abstract and references), with up to 150 references and 4-6 
tables and/or figures. 





o Instructions for Figure preparation 
o Instructions for Table preparation 
o Instructions for Supplemental Material 
Letter to the Editor (Back to Top) 
 A Letter to the Editor can offer brief, objective, and constructive comments or 
criticism concerning previously published articles or provide other 
communication of general interest to the readership. Such correspondence 
submissions are not a venue for Case Reports, and authors must attest during the 
submission process, in their cover letter, that a case description is not included in 
their correspondence. 
 A Letter to the Editor should be brief, with no more than 500 words. Three or 
fewer references, a small table or a pertinent illustration may be provided. 
 All Letters to the Editor should be submitted via the Anesthesia & 
Analgesia Online Submission and Review System and not via email or postal 
service. 
 Letters are edited by the Correspondence Editor, sometimes extensively, to 
sharpen their focus. A Letter to the Editor may be sent for peer review, at the 
discretion of the Correspondence Editor. 
 A Letter to the Editor that is written in response to a published paper must be 
submitted no later than 3 months after the first of day of the month of the original 
article’s print publication date. 
 Instructions for Manuscript preparation 
Book and Multimedia Reviews (Back to Top) 
o A Book and Multimedia Review reports on a current publication about 
anesthesiology, perioperative medicine, critical care medicine, or pain 
medicine. 
o Publishers interested in having their book or multimedia material reviewed 
by the Journal should first contact our Media Reviews editor 
at: bookreviews@iars.org. 
o A Book Reviews contains no more than 750 words. 
o Instructions for Manuscript preparation 
Meeting Report (Back to Top) 
o A Meeting Report is a scholarly outline of the program and content of a 
scientific meeting. 
o A Meeting Report may be organized temporally (day by day) or 
thematically (topic by topic). 
o Authors interested in submitting meeting reports should first contact our 
Media Reviews editor at bookreviews@iars.org to confirm that the 





o A Meeting report does not have an Abstract and contains no more 
than 1500 words. 
o Instructions for Manuscript preparation 
A&A Practice (Back to Top) 
Please note that when submitting a manuscript to A&A Practice, go 
to http://www.editorialmanager.com/aa/default.aspx and select “A&A Practice” as the 
submission type. 
 An A&A Practice submission includes a Title Page and an unstructured Abstract 
with a maximum of 100 words. 
 If applicable, the title for a case report should include the specific words “Case 
Report.” 
 An A&A Practice submission includes an Introduction; Description of the case, 
project, initiative, setting, or scenario; Discussion; and References. 
 An A&A Practice submission contains no more than 1500 words (not counting 
the references), with no more than 15 references. 
 Including pertinent figures, illustrations, tables, and/or supplementary digital and 
video and audio material that expands the reader’s understanding of the case 
report is strongly encouraged. 
o Study Reporting Requirement (EQUATOR) 
o Instructions for Manuscript preparation 
o Instructions for Figure preparation 
o Instructions for Table preparation 
o Instructions for Supplemental Material 
For more information about A&A Practice and to view examples of its published 
manuscripts, visit: http://journals.lww.com/aacr. 
As of January 1, 2018, all Echo Rounds and Echo Didactics articles will be 
published in A&A Practice. Please adhere to the following, otherwise unchanged 
submission details for Echo Rounds and Echo Didactics submssions. 
Echo Rounds (Back to Top) 
o Echo Rounds provide a focused discussion of a unique or interesting 
perioperative clinical situation in which ultrasound was central to the 
clinical management. Submissions must provide succinct teaching points 
on echocardiographic/ultrasound views, techniques or calculations. Their 
teaching content must be supported by the current literature or standard 
reference texts of echocardiography, preferably those most accessible to 





o Authors are advised to examine previously published Echo Rounds (either 
via the Table of Contents or www.anesthesia-analgesia.org) to avoid 
submission of previously published topics. 
o Echo Rounds should not be construed and presented as "mini Case 
Reports." Therefore, only the most relevant clinical details and specific 
echo findings should be succinctly presented in the first one-third of the 
manuscript. The specific echo findings and didactic discussion of the echo 
topic(s) should comprise the subsequent two-thirds of the manuscript. 
o Echo Rounds include a Title Page but not an Abstract. 
o Echo Rounds are short reports with no more than 800 words (not counting 
the Abstract and references) and no more than 6 references. 
o Echo Rounds should be accompanied by 1-3 echocardiographic still 
images and 1-3 video clips with legends. The video clips will be 
available online. The still images usually, but not always, correspond to 
the respective video clip(s). Figures and clips should be appropriately 
labeled (e.g., arrows, abbreviations of anatomic structures, etc.). Authors 
may elect to consolidate consecutive time segments into a single clip, 
although adequate viewing time for each segment must be provided to 
clearly illustrate the primary findings being discussed in the text. 
o One simple table is also allowed. 
o Study Reporting Requirement (EQUATOR) 
o Echo Rounds Submission Checklist 
o Required HIPAA Waiver 
o Instructions for Manuscript preparation 
o Instructions for Figure preparation 
o Instructions for Table preparation 
o Instructions for Supplemental Material 
o Instructions for Video Preparation 
Echo Didactics (Back to Top) 
o Echo Didactics are solicited submissions presenting a practical 
clinical review of a particular ultrasound topic (e.g., important 
measurements, specific anatomic or physiologic evaluation, and current or 
emerging technologies) related to transesophageal, surface/transthoracic, 
epicardial, epiaortic or intravascular echocardiography. 
o Echo Didactics include a Title Page but not an Abstract. The author should 
instead provide 3 or 4 bulleted teaching points summarizing the most 
important teaching points. 
o Echo Didactics submissions start with an index case, which is a 1-2 
sentence clinical scenario to preface the content. 
o The main focus of Echo Didactics should be a discussion of the most 
relevant background, the "nuts and bolts" of the assessment, measurement, 
or imaging, and new concepts. 
o Echo Didactics contain no more than 1500 words (not counting the 





o Echo Didactics should include 1 to 3 high-resolution figures and 1 to 3 
video clips, which can be composite videos. Figures and clips should be 
appropriately labeled (e.g., arrows, abbreviations of anatomic structures, 
etc.). Authors may elect to consolidate consecutive time segments into a 
single clip, although adequate viewing time for each segment must be 
provided to clearly illustrate the primary findings being discussed in the 
text. 
o One simple table is also allowed. 
o Study Reporting Requirement (EQUATOR) 
o Echo Didactics Checklist 
o Instructions for Manuscript preparation 
o Instructions for Figure preparation 
o Instructions for Table preparation 
o Instructions for Supplemental Material 
SECTION 2: ARTICLES TYPES AT A GLANCE (Back to Contents) 
Particular attention should be paid to the listed word count, reference count, and 
table/figure limits for each article type, both for an initial submission and any 
subsequent revisions. 
These listed word count, reference count, and table/figure limits will be strictly 
enforced, resulting in a manuscript being returned to the author(s) for revision 
prior to any initial or a subsequent peer-review. 
SECTION 3: STANDARDIZED STUDY REPORTING REQUIREMENTS (Back 
to Contents) 
A. Enhancing the Quality of and Transparency of Health Research (EQUATOR) 
Network 
The Enhancing the Quality of and Transparency of Health Research (EQUATOR) 
Network was created to monitor and to propagate the proper use of guidelines to improve 
the quality of scientific publications by promoting transparent and accurate reporting of 
human subjects, health services, and animal research. 
As advocated by the EQUATOR Network, Anesthesia & Analgesia strongly 
encourages adherence to the applicable statement/guidelines and checklist for all 
submitted research-related manuscripts (see Table below). Manuscripts adhering to 
the applicable statement/guidelines and checklist will typically receive a more 
favorable review by the Journal. 
Adhering to the applicable statement/guidelines and checklist promotes consistent study 
design and manuscript content, which are major advantages for the Journal’s authors, 





Authors should consult the EQUATOR Network webpage and/or the webpage URL or 
citation listed in the Table below for the most current version of the specific, 
applicable statement or guideline and its checklist. 
 The applicable study checklist should be completed and uploaded under the 
EQUATOR Checklist File category at the time of initial manuscript 
submission via Editorial Manager. 
Acronym Full Title of Guideline Webpage URL or Citation 
CONSORT 
Consolidated Standards of Reporting 




Transparent Reporting of Evaluations 




Strengthening the Reporting of 




Preferred Reporting Items for 









Standards for Reporting Qualitative 
Research 
Consolidated Criteria for Reporting 




Consolidated Health Economic 






Standards for Accurate Reporting of 
Diagnostic Tests 
Transparent Reporting of a 
Multivariable Prediction Model for 









Animal Research: Reporting of In 
Vivo Experiments 
http://www.nc3rs.org.uk/arrive-guidelines 
CARE Case Reports http://www.care-statement.org/ 
* The main CONSORT Statement is based on the “standard” two-group parallel design. 





different designs (e.g., cluster, non-inferiority and equivalence, or pragmatic trials), 
interventions (e.g., herbal medicinal, non-pharmacological, or acupuncture) and data 
(e.g., harms), for which specific CONSORT Extensions exist. 
B. SPECIFIC STUDY TYPE AND ASSOCIATED PUBLISHED GUIDELINE 
1. Randomized Controlled Trials. Authors reporting the results of a randomized 
controlled trial must follow the CONSORT statement and provide a completed 
CONSORT checklist. Authors must also provide a CONSORT flow diagram as Figure 1 
of the submitted manuscript. 
Please note that there are CONSORT Extensions for several different types of 
randomized trials, and the most applicable Extension should be followed by authors. 
2. Non-Randomized Controlled Trials. Authors reporting the results of a non-
randomized controlled trial must follow the TREND statement and provide a 
completed TREND checklist. 
3. Observational Studies. Authors reporting the results of a cohort, case-cohort, nested 
case-control, case-control, or cross-sectional study (or any other type of 
observational study of human subjects), a case series of > 4 patients, or a retrospective 
data collection study must follow the STROBE statement and provide a completed 
STROBE checklist. 
Authors submitting the results of such a quantitative observational study should clearly 
indicate (a) whether the primary outcome(s) were defined and established a prioriat 
initiation of the study design or were created post hoc during data exploration (“data 
mining”) and accompanying statistical analysis and (b) whether subgroup or sensitivity 
analyses were identified and established a priori or post hoc. For studies evaluating a 
treatment effect, indicate whether and how a clinically meaningful effect size was 
defined, once again either a priori or post hoc. 
For further insights and directions, see Eisenach JC, Kheterpal S, Houle TT. Reporting of 
Observational Research in ANESTHESIOLOGY: The Importance of the Analysis Plan. 
Anesthesiology. 2016;124(5):998-1000. 
For a single case study or small case series of < 3 patients, the STROBE statement is not 
applicable but instead the CARE statement (see below) should be followed. 
4. Systematic Review or Meta-analysis. Authors reporting a systematic 
review or meta-analysis of randomized trials or cohort studies must follow the 
PRISMA (previously named QUOROM) Statement and provide a completed PRISMA 






5. Quality Improvement Research. Authors reporting the results of a quality 
improvement study must follow the SQUIRE 2.0 guidelines and provide a completed 
SQUIRE 2.0 checklist. 
6. Qualitative Research. Authors reporting the results of a qualitative study (e.g., in-
depth interviews and focus groups) must provide a completed SRQR checklist. 
Alternatively, authors reporting the results of a qualitative study can provide a 
completed COREG checklist. 
7. Mixed Methods Research. No definitive guidelines have been created for mixed 
(qualitative/quantitative) research. However, authors reporting the results of a 
mixed methods research study can reference the Good Reporting of A Mixed 
Methods Study (GRAMMS) framework. 
See the following pertinent references: 
Cameron RA, Trudy D, Scott R, Ezaz A, Aswini S. Lessons from the field: Applying the 
Good Reporting of A Mixed Methods Study (GRAMMS) framework’. Electronic Journal 
of Business Research Methods. 2013. https://works.bepress.com/roslyn_cameron/131/ 
O'Cathain A, Murphy E, Nicholl J. The quality of mixed methods studies in health 
services research. J Health Serv Res Policy. 2008;13(2):92-98. 
O'Cathain A, Murphy E, Nicholl J. Three techniques for integrating data in mixed 
methods studies. BMJ. 2010 Sep 17;341:c4587. 
8. Health Economic Evaluation Research. Authors reporting the results of a health 
economic evaluation research study must follow the CHEERS guidelines and provide a 
completed CHEERS checklist. 
9. Diagnostic Accuracy. Authors reporting a study of the accuracy of a diagnostic 
test must follow the STARD statement and provide a completed STARD checklist. 
Authors must also provide a STARD flow diagram as Figure 1 of the submitted 
manuscript. 
Alternatively, authors reporting studies of the accuracy of diagnostic tests can follow the 
TRIPOD Statement and provide a completed TRIPOD checklist. 
10. Genetic Association Studies. Authors reporting a genetic association study must 
follow the STREGA guidelines and must submit a completed STREGA checklist. 
11. Animal Studies. Authors reporting an animal study must follow the ARRIVE 
guidelines and must submit the ARRIVE checklist. 





o Authors must submit a completed checklist for an Echo Rounds 
submission Required Echo Rounds Submission Checklist 
o Authors must submit a completed checklist for an Echo Didactics 
submission Required Echo Didactics Submission Checklist 
o Echo Rounds or Echo Didactics for publication by A&A Practice must be 
prepared in accordance with the requirements of HIPAA privacy 
regulations (See Section 7.E. A&A Echo Rounds and Echo Didactics 
Compliance with HIPAA Privacy Regulations). 
13. Case Reports. Authors reporting the details of a case study of a single patient or 
a case series of <3 patients must follow the CARE Guidelines and submit a completed 
CARE checklist. 
Please note that in the CARE guidelines for Case Reports, item #13 states: “Informed 
Consent: The patient should provide informed consent for this case report.” 
However, per the CARE guidelines, for case reports originating from outside the United 
States written patient consent must be obtained. 
Nevertheless, Case Reports for publication by Anesthesia & Analgesia from the United 
States must be prepared in accordance with the requirements of HIPAA privacy 
regulations (See Section 7.D. A&A Practice Compliance with HIPAA Privacy 
Regulations). 
In clinical case reports, authors should state whether they have reported serious adverse 
events to the manufacturer, United States Food and Drug Administration (FDA), or other 
governmental regulatory agency. 
SECTION 4: STANDARDS FOR STATISTICAL 
METHODS AND STATISTICAL REPORTING (Back to Contents) 
All authors who are presenting data and data analyses in their manuscripts 
submitted to the Journal are now required to attest via Editorial Manager that they 
have reviewed sections 4A, 4B, 4C and 4D located below and have implemented all 
of the relevant items. 
This should be done preferably before implementing their study data collection but 
certainly as they undertook their statistical analyses and prepared their manuscript for 
initial submission and any requested revision(s). 
While Anesthesia & Analgesia has elected not to implement a required formal 
statistical checklist to be completed and submitted by authors, adhering to the 
guidelines below will substantially improve chances of publication and avoid delays 





Authors may also find this editorial informative: Mascha EJ, Vetter TR. The Statistical 
Checklist and Statistical Review: Two Essential Yet Challenging Deliverables. Anesth 
Analg. 2017 Mar;124(3):719-721. 
A. Statistical Analyses and Methods as Promulgated by the Statistical Analyses and 
Methods in the Published Literature (SAMPL) Guidelines 
As advocated by the EQUATOR Network, Anesthesia & Analgesia strongly endorses 
adherence to the Statistical Analyses and Methods in the Published Literature 
(SAMPL) Guidelines. 
Please see Lang TA, Altman DG. Basic statistical reporting for articles published in 
biomedical journals: The “Statistical Analyses and Methods in the Published Literature” 
or “The SAMPL Guidelines.” Handbook, European Association of Science Editors. 
2013:23-6. 
The SAMPL Guidelines can be accessed at http://www.equator-network.org/reporting-
guidelines/sampl/. 
BASIC STATISTICAL METHODS AND REPORTING THAT SHOULD BE 
INCLUDED IN ALL QUANTITATIVE MANUSCRIPTS. 
THESE ITEMS ARE COMMONLY MISSING OR DEFICIENT IN SUBMITTED 
MANUSCRIPTS, LEADING TO A LENGTHIER STATISTICAL REVIEW. 
AUTHORS ARE THUS STRONGLY ENCOURAGED TO PROACTIVELY 
ADDRESS ALL OF THESE ISSUES. 
B. For All Studies That Include Data Analysis and/or Estimation: 
1. Primary and secondary outcomes. Primary and secondary outcomes must be 
clearly identified and distinguished in the Abstract, Methods, Statistical Methods, 
Results, and Discussion. The designation as primary or secondary outcome should 
have been decided a priori. If true, this should be stated; if not, the reasons why 
should be explained. While it is acceptable to present findings not anticipated in 
the study design, these should be clearly identified as post hoc observations. 
2. Detailed statistical methods section. The statistical methods section needs to 
closely follow the stated study hypotheses or aims (i.e., not a generic list of tests 
that could apply to most any study and its manuscript) and to be sufficiently 
detailed, including all conducted analyses. 
3. Assumptions. Report how the key assumptions of the conducted statistical 
analyses were assessed and confirmed. For example: one-sided versus two-sided 
tests of statistical confidence. 
4. Type I error/multiple testing. Explain how a Type I error is protected at the 
given level (e.g., 0.05), if there are multiple primary outcomes or multiple testing 





significance level and the significance criterion (P-value cut-point) that are 
applied to individual comparison tests. 
Note: Authors are discouraged from using the argument that adjusting for 
multiple comparisons or multiple testing should not be done because it increases 
the risk of a Type II error (decreases power). While it is true that more stringent 
significance criterion decreases power, that is the price of multiple testing, and the 
sample size needs to be increased accordingly. Neglecting to adjust for Type I 
error can lead to extremely high chance of some or many of a study’s statistically 
significant results being false positives. The goal should be to focus on key 
outcomes and exposures in the study design phase. 
5. Justify the sample size. Whether the findings are positive or negative, authors 
should explain how the sample size was derived. Authors should also declare the 
planned (a priori) power or available (post-study) power to detect clinically 
important differences in the primary outcome. These are key features of the study 
design. This section should appear immediately after the statistical methods are 
detailed. 
6. For post-study power (not calculated a priori), consider what difference would be 
clinically important, independent of the observed results. Post-study power should 
NOT be based on the observed differences, but rather on what the authors (and 
readers) would consider to be clinically important. For an estimation study with 
no statistical comparisons being made (e.g., estimating prevalence or diagnostic 
accuracy), report the planned or available width of the confidence interval for 
primary endpoint. A sample size calculation needs to have sufficient information 
to be reproducible by the reader. 
Note: Requiring authors to report on power to detect clinically important 
differences, as mentioned above, does not take away the importance of reporting 
confidence intervals and interpreting them well. Whereas power speaks to the 
design of the study, confidence intervals give important information on the 
available evidence from the observed data. Both are important and needed. 
For example, suppose in their design phase, authors had 80% power to detect a 
relative risk of 0.50 or stronger (low power). Then suppose the estimated risk 
ratio (RR) confidence interval from the study was 0.70 (0.30, 1.9). This study is 
not conclusively negative since clinically important effects are contained within 
the confidence limits. Reporting a priori low power to detect clinically important 
differences (independent of what was actually observed), in addition to the 
observed wide observed confidence interval limits, makes a negative conclusion 
even stronger. 
7. Results section should follow clearly from the statistical methods and study 
objectives. Primary and then secondary aims should be addressed in sequence, 
with clear differentiation. No new statistical methods should be introduced in the 





8. Report treatment effect estimates and variability (standard error or confidence 
interval) of treatment effect estimate at least for the primary outcome(s). 
Confidence intervals and P-values must be reported in both the Abstract and 
Results sections. Also report confidence intervals for estimates of incidence, 
prevalence, when they are the primary outcome. Confidence intervals for the 
primary outcomes should be interpreted as the best evidence for where the 
treatment effect or association of interest may fall. Non-significant results should 
be given more weight as conclusively negative when the confidence interval does 
not include what authors or others would consider to be clinically important 
effects. 
9. Similar/equivalent. When conducting tests for superiority, it is not appropriate to 
make claims of groups being “equivalent” or “similar.” Non-significant results 
from superiority tests should only make claims of no difference being found. 
A specific design (equivalence study) and tailored analytic methods are required 
before one can make claims of equivalence or similarity. 
10. Baseline comparisons. In a randomized trial, authors should not include P-values 
or related tests comparing randomized groups on baseline characteristics. Rather, 
simply discuss whether clinically important differences in the observed numbers 
are apparent or not. Since there is no hypothesis being tested at baseline, the P-
values are not appropriate. Instead consider assessing balance using standardized 
difference (guidance is that absolute standardized difference greater than 0.10 is 
evidence of imbalance). In statistical methods, say what you had planned to do, if 
anything, if clinical imbalances were found at baseline (e.g., include those 
variables in a multivariable model when assessing association between exposure 
and outcome.). 
11. On the other hand, for nonrandomized studies, comparing groups on baseline 
characteristics using statistical tests is important and highly recommended. 
12. Conclusions. Conclusions should not go beyond what was tested or assessed in 
the study, and should focus on primary endpoint(s). In particular, observational 
studies—whether retrospective or prospective—can only identify association 
between a variable and an outcome. Do not use language that would imply a 
cause and effect relationship (see below). 
C. Additional Elements for Non-Randomized Observational Studies Assessing an 
Association Between Exposure and Outcome. However, still Follow Part A and Part 
B above. 
1. Confounding. Address potential confounding of the relationship of interest as 
thoroughly as possible using multivariable regression, propensity score methods, 
or other methods. Since the goal is typically to adjust for as much confounding as 
possible, it is usually neither desired nor ideal to use a so-called parsimonious 
model when considering which variables to adjust for. Adjustment should instead 
be more liberal. When limited adjustment is made, for whatever reason, list this as 





Example: In retrospective database studies, researchers may assess the 
association between an exposure of interest (such as receiving an intraoperative 
blood transfusion or not) and a major postoperative complication or event. Since 
the exposure groups are not randomized, they may differ on baseline variables 
(e.g., age, sex, BMI, comorbidities, ASA physical status), variables which 
themselves may be strongly associated with the outcome variable. Researchers 
will want either to control for such variables in a multivariable model when 
assessing the association of interest, or alternatively to use propensity score (PS) 
methods either to match exposed and non-exposed patients on the set of 
potentially confounding variables or alternatively to weight by or adjust for the 
PS. With each method, the goal is to reduce confounding. 
2. Causation versus association. Avoid using language suggesting causation, such 
as the exposure "reduced" the outcome, or "effect" of the exposure on outcome. 
Also avoid referring to an independent variable as a "risk factor" in an 
observational study. Instead, state and discuss that an "association" was observed 
between exposure and outcome. 
3. When discussing observational results, please be as conservative as possible. 
Many observational studies demonstrate—in essence—that sicker patients do 
worse; this is not a novel finding! Methodologic limitations, including the 
potential for unidentified confounding, should be transparently discussed. A 
statement such as “further research is needed” can be greatly enhanced with a 
further few sentences describing how prospective research should be conducted, 
and what the available power to detect a difference might be. 
D. Additional Details for All Studies 
1. P-values. Report all actual P values, not “NS.” P-values should usually be 
rounded to 2 or 3 decimal places. 
2. Say “multivariable” instead of “multivariate” when there are multiple independent 
variables and a single outcome variable. 
3. Tables should include the patient or unit denominator (sample size), and should 
reference the utilized statistical methods in the table footnotes. 
4. Tables and figures should stand alone. Tables and figures, along with their 
legends and footnotes, should include enough information about what was done 
statistically to basically stand alone, independent of the statistical methods 
subsection of the manuscript. 
5. Trend. Authors should not say that the nearly statistically significant result 
represents a trend in the data. Neither should authors say “there was an effect of X 
on Y” and then say that it was non-significant—instead, simply state that it was 
non-significant or that no association was found. 






An Electronic Copyright Transfer and Disclosure Questionnaire is completed by the 
corresponding author during submission. 
Upon submission, the co-authors are emailed a hyperlink to verify their co-authorship 
and complete the electronic Copyright Transfer and Disclosure Form within Editorial 
Manager. 
Questions About the Copyright Transfer and Disclosure Form? 
Please contact our editorial office at editor@anesthesia-analgesia.org 
SECTION 6: OPEN ACCESS OPTION FOR PUBLICATION (Back to Contents) 
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual 
unrestricted online access to their published article to readers globally, immediately upon 
publication. The article processing charge for Anesthesia & Analgesia is $3,200 (for 
CCBY-NC-ND license, $4,000 for CCBY) and for A&A Practice is $600 (CCBY-NC-
ND only). Please see the Open Access page for more details. 
 
SECTION 7: ANESTHESIA & ANALGESIA AND A&A Practice MANUSCRIPT 
PREPARATION (Back to Contents) 
Manuscript Organization 
Title Page 
Abstract (when required) 












Video instruction for Echo Rounds and Echo Didactics 
Supplemental Material 
Additional Information 
      Units of Measurement 
      Abbreviations 
      Drug Names and Equipment 
      Statistical Analysis 
      Patient Identification 
Permissions 
Language Editing Services 
Manuscript Organization (Back to Top) 
ALL articles should be arranged in the following order. 
1. Manuscript, as a single file, consisting of Title Page, Abstract (not required for all 
article types – see Articles At A Glance), Body Text, References 
2. Tables (each Table should be a separate .doc file or placed at the end of the 
manuscript file) 
3. Figure Legends (placed consecutively, in numerical order, all on the same page) 
4. Figures (each Figure should be uploaded as a separate file) 
5. Appendices (each Appendix should be a separate file) 
Title Page (Back to Top) 
 Article Title 
 First name, middle initial, and last name of each author, with their highest 
academic degree (M.D., Ph.D., etc.), and institutional affiliations. 
 Name, mailing address, phone number, and e-mail address of the corresponding 
author. 
 Disclosure of funding received for the work from National Institutes of Health 
(NIH), Wellcome Trust, Howard Hughes Medical Institute (HHMI), and all other 
financial support, including departmental or institutional funding. If no funding 
received, state Financial Disclosures: None 
 Please list any conflicts of interest the authors have had within the 36 months of 
submission. If no conflicts, state Conflicts of interest: None 





 List the word count of the Abstract, Introduction, and Discussion. Also list 
the overall word count for the entire body of text (excluding Abstract and 
References). 
 Abbreviated Title (running head) that states the essence of the article (< 50 
characters). This is not required for all article types (see above). 
 List each author’s individual contribution to the manuscript. For each author, 
please list the individual contribution using the following text: “Author Name: 
This author helped…” 
Abstract (Back to Top) 
Manuscript Type
 
Abstract Type Number of words 
Original Clinical Research Report
 
Structured 400 
Original Laboratory Research 
Report 
Structured 400 
Brief Report Unstructured 100 
Narrative Review  Unstructured 400 
Systematic Review Unstructured 400 
Meta-Analysis  Structured 400 
Editorial NA NA 
The Open Mind NA NA 
Special Article Unstructured 400 
Echo Rounds  NA NA 
Echo Didactics  3 bulleted teaching points NA 
Letter to the Editor NA NA 
Book and Multimedia Review NA NA 
Meeting Report NA NA 
Case Report Unstructured 100 
Key Points Summary (Back to Top) 
For Original Clinical/Laboratory Research Reports and Meta-Analyses, a "Key Points" 
summary should be included directly underneath the structured abstract. The key points 
summary should describe the Question, Findings, and Meaning, each composed of one 
sentence. Please format the summary as three bullet points: 
 Question: [One Sentence Text] 
 Findings: [One Sentence Text] 
 Meaning: [One Sentence Text] 





The body of the manuscript should typically be divided into four parts (does not apply to 
all article types – See Article Types At A Glance): 
 Textual material (body text, tables, figure legends etc.) should be submitted as a 
.doc or .docx word processing file 
 12 point Arial or Times New Roman font 
 Introduction (new page). This should rarely exceed one page in length. 
o Should ideally contain only 4 to 5 short paragraphs: (1) significance, (2) 
background, (2) rationale, and (3) the study’s aims or objectives and if 
applicable, (5) primary study hypothesis, and if appropriate, the secondary 
study hypothesis. 
o Avoid the temptation and frequent tendency to provide an extensive 
literature review in the Introduction. 
 Methods (new page) 
o A subsection entitled “Statistical Analysis” should appear at the end of the 
Methods section when appropriateA statement that the study was 
approved by the appropriate IRB/Research Ethics Committee and written 
informed patient consent was obtained, or that the requirement for written 
informed consent was waived. (See section C Protection of Human 
Subjects). 
o If applicable, authors should include their clinical trial registration 
number, registry, principle investigator and date of registration. (See 
section G Registration of Clinical Trials) 
o A statement indicating the author has followed the appropriate 
EQUATOR guidelines should be included in the Methods section. 
 Example: “This manuscript adheres to the applicable CONSORT 
guidelines.” 
o A subsection entitled “Statistical Analysis” should appear at the end of the 
Methods section when appropriate 
 Results (new page) 
 Discussion (new page). Focuses on the findings in the current work 
Acknowledgements (Back to Top) 
For acknowledgement of individuals or organizations, provide complete name, degrees, 
academic rank, department, institutional affiliation, city, state, and country. Add 
description of the contribution to the study. 





 Anesthesia & Analgesia and A&A Practice follow the American Medical 
Associate (AMA) citation style; Consult the American Medical Association 
Manual of Style, 10th ed., New York, Oxford University Press, 2007, for style. 
 Number references (as superscripts) in the sequence they appear in the text. 
 In text, tables, and legends, identify references with superscript Arabic numerals. 
 If there are 6 or fewer authors/editors, list all 6; if there are more than 6, list the 
first 3 followed by “et al.” 
 Abbreviate names of journals according to the journals abbreviation list 
maintained by PubMed 
 Manuscripts “In Press” – A “manuscript in press” is defined as an article that has 
been accepted for publication, but has not yet been published by the accepting 
journal, in print or online and is being cited as basis for the study being described 
in the submitted manuscript. Please submit an electronic copy (Word, PDF) of 
any "In Press" manuscript that is cited in the reference list, labeled as "In Press, 
Reference # ___." 
Tables (Back to Top) 
 Anesthesia & Analgesia and A&A Practice follow the American Medical 
Associate (AMA) table format. 
 Tables should be uploaded as a separate Word file or presented in the main 
document word file, just after the references. 
 Use a separate page for each table. 
 Individual tables should not exceed two typed pages. If a table exceeds two typed 
pages, start a new table on the subsequent page. 
 For any table that exceeds two typed pages and cannot be divided into a new 
table, the table should be submitted as a supplemental digital content file (see 
formatting requirements for Supplemental Digital Content files below). 
 Double-space all table material. 
 Do not submit tables as photographs or pasted images. Tables should be black and 
white only. 
 Number the tables consecutively and cite them consecutively (on first instance) in 
the text. 
 Do not create multi-part tables (e.g., Table 1A, Table 1B). Such tables should 
instead be cited as "Table 1," "Table 2," etc. 
 Each table should have a brief title. 
 Each column in a table should have a brief column header name. 
 Use footnotes (not table titles or column headings) for explanatory matter and 
definitions of abbreviations. Abbreviations must be described with footnotes even 
if they are defined in the text or in other tables. 
 For footnotes within a Table, use lower-case italicized letters in sequential 
alphabetical order. 
 If you include a block of data, a table, or a figure from another source, whether 





Appendices (Back to Top) 
 Uploaded as a separate file 
 Each appendix must be cited within the text, in consecutive order. 
 Appendix content counts towards the table and/or figure limits. If the inclusion of 
an appendix exceeds the table and/or figure limit for the respective article type, 
submit the appendix as a supplemental digital content file. 
Figure Legends (Back to Top) 
 Supply a legend for each figure. 
 Group Figure legends on a single page just after the references 
 If a figure has multiple panels (e.g., left, right or A, B, C) please specify each 
panel in the legend. 
 Repeat definitions of any abbreviations used in the legend 
Figures (Back to Top) 
 Figures should be uploaded as separate .tiff, .jpeg, .pdf or .pptx files. Figures will 
have to be uploaded at a resolution of 300 dpi or higher at acceptance. 
 Figures with multiple panels should be condensed into a single file for each figure 
(for example, Figure 1A through 1F should be in one file, Figures 2a through 2F 
should be in a second file, etc.). Each individual panel should be labeled with a 
capital letter. 
 Anesthesia & Analgesia and A&A Practice publish in full color, and encourage 
authors to use color to increase the clarity of figures. 
 Standard colors should be used (black, red, green, blue, cyan, magenta, orange, 
and gray). 
 Avoid colors that are difficult to see on the printed page (e.g., yellow) or are 
visually distracting (e.g., pink). 
 Figure backgrounds and plot areas should be white, not grey. 
 Axis lines and ticks should be black and thick enough to clearly frame the image. 
 Axis labels should be large enough to be easily readable and printed in black. 
 Number figures consecutively. Supply a brief title for each. Cite figures in the text 
in consecutive, numerical order on first instance. 
 If a figure has already been published, acknowledge the original source. You must 
obtain and submit written permission from the copyright holder to reproduce the 
material when you submit the manuscript for review. Unpublished figures require 
permission of the author. Permission is required to reproduce any previously 
published material except for documents or figures in the public domain. See 
Permissions 
 Define all abbreviations used in each figure. Repeat definitions of any 
abbreviations used in subsequent legends. 





The video clip(s) accompanying Echo Rounds or Echo Didactics submissions should 
conform to the following: 
 Formatted in MPEG, QuickTime (MOV), Windows Media Video (WMV) or 
MP4. 
 Play on both Windows and Macintosh platforms. The review process will be 
delayed if the Editorial Office cannot play your video clip. 
 Individual size should not exceed 15 MB. Use video-compression software to 
reduce video size if necessary. 
 Optimal video frame dimensions of 480 x 360 pixels and 640 x 480 pixels. 
Videos of 320 x 240 pixels have inadequate resolution for teaching. 
 Duration of individual video clip should be less than 15-25 seconds. 
 Combinations of clips: If you combine several video clips, for example several 
TEE echocardiographic loops, please provide adequate time for each segment, 
and leave a suitable gap between the videos. Use appropriate labeling to ensure 
that the viewer can understand the timing of the pathology and events. Labeling 
can be added with video editing programs such as Adobe Premiere or iMovie. 
 Authors should complete a video checklist form for each video when submitting a 
revised manuscript. The video checklist form provides the information necessary 
to upload the video on the journal website’s video gallery. 
The figure(s) accompanying Echo Rounds or Echo Didactics submissions should 
conform to the following: 
 Formatted in high-resolution JPEG or TIFF formats. 
 Individual size should not exceed 500 KB (to permit adequate resolution for 
printing). 
Supplemental Material (Back to Top) 
 Authors may submit separate supplemental material to enhance their article's text 
and to be considered for online-only posting. 
 Supplemental material may include the following types of content: text 
documents, graphs, tables, figures, audio, and video. 
 Cite all supplemental digital content consecutively in the text. 
 Citations should include the type of material submitted, should be clearly labeled, 
and should include a sequential number (Example “Supplemental Figure1”, 
“Supplemental Table 1”, “Supplemental Video 1”). 
 Supplemental Legends should be submitted at the end of the manuscript file and 
should provide a brief description of the supplemental content. For example: 
“Supplemental Table 1: Lists all medications used in this study.” 
 Each supplemental digital content file must be composed to standalone. For 
example, tables and figures must include titles, legends, and/or footnotes, 
following journal style, so the viewer can fully understand the supplemental 
content on its own. Production will not make any edits to the supplemental files; 





 It is recommended to group multiple supplemental figures/tables into one 
supplemental digital content file when submitting. Each file will be given a 
permanent hyperlink when the Publisher prepares the supplemental digital content 
for posting. To avoid excessive hyperlinks in your publication, please group 
figures/tables. 
 For audio and video files, enter the author name, videographer, participants, 
length (minutes), and size (MB) of file in Editorial Manager. Authors should 
mask patients’ eyes and remove patients’ names from supplemental digital 
content unless they obtain written consent from the patients and submit written 
consent with the manuscript. Copyright for video or audio supplemental digital 
content will be required upon acceptance. 
 For a list of acceptable file types and size limits, please review LWW's 
requirements for submitting supplemental digital 
content: http://links.lww.com/A142 
Additional Information (Back to Top) 
1. Units of Measurement 
Use metric units. The units for pressures are mmHg or cmH2O. Diagonal slashes 
are acceptable for simple units, e.g., mg/kg; when more than two items are 
present, negative exponents should be used, i.e., ml · kg-1 · min-1 instead of 
ml/kg/min. 
2. Abbreviations 
Define all abbreviations except those approved by the International System of 
Units for length, mass, time, temperature, amount of substance, etc. Do not create 
new abbreviations for drugs, procedures, experimental groups, etc. 
3. Drug Names and Equipment 
Use generic names. If a brand name must be used, insert it in parentheses after the 
generic name. Provide manufacturer's name, city, state, and country. Be careful 
about the use of trademarked terms (e.g., ThrombelastographyTM, TEGTM, etc.). 
4. Statistical Analysis 
Detailed statistical methodology must be reported. Describe randomization 
procedures and the specific tests used to examine each part of the results; do not 
simply list a series of tests. Care should be taken with respect to a) parametric vs. 
nonparametric data, b) corrections for multiple comparisons, and c) rounding 
errors (summary statistics should not contain more significant digits than the 
original data). Median range (or percentiles) is preferred for nonparametric data. 





Do not use patients' names, initials, or hospital numbers. An individual (other than 
an author) must not be recognizable in photographs unless written consent of the 
subject has been obtained and is provided at the time of submission. 
Permissions (Back to Top) 
Authors must submit written permission from the copyright owner (usually the publisher) 
to use direct quotations, tables, or illustrations that have appeared in copyright form 
elsewhere, along with complete details about the source. Any permission fees that might 
be required by the copyright owner are the responsibility of the authors requesting use of 
the borrowed material, not the responsibility of Wolters Kluwer or the editorial office. To 
request permission and/or rights to use content from Anesthesia & Analgesia, access 
the Copyright Clearance Center) and enter Anesthesia & Analgesia in the ‘Get 
Permissions’ field in the upper-right corner. Please note: Permission will not be granted 
to adapt figures that have been previously published in Anesthesia & Analgesia. Contact 
the Editorial Office at editor@anesthesia-analgesia.org for further information. 
Language Editing Services (Back to Top) 
Articles submitted to the Journal must be written with a solid basis of English language. 
Awkward or non-intelligible English grammar and syntax can adversely affect the review 
process and this likelihood of acceptance of a manuscript. Authors whose native 
language is not English should thus strongly consider having their manuscript copy-
edited by a native English language medical/technical writer prior to initial 
submission. 
If you need assistance in preparing a manuscript for submission, our publisher, Wolters 
Kluwer, in partnership with Editage, offers a range of editorial services for a fee, 
including: 
 Premium Editing: Intensive language and structural editing of academic papers to 
improve the clarity and impact of your manuscript. 
 Advanced Editing: A complete language, grammar, and terminology check to 
give you a publication-ready manuscript. 
 Translation with Editing: Write your paper in your native language and Wolters 
Kluwer Author Services will translate it into English, as well as edit it to ensure 
that it meets international publication standards. 
 Plagiarism Check: Helps ensure that your manuscript contains no instances of 
unintentional plagiarism. 
 Artwork Preparation: Save precious time and effort by ensuring that your artwork 
is viewed favorably by the journal without you having to incur the additional cost 
of purchasing special graphics software. 
For more information regarding Wolters Kluwer Author Services and to receive a quote 
for your manuscript, please visit wkauthorservices.editage.com. Please note that use of 





in any way imply a guarantee, or even a likelihood, of acceptance of your manuscript 
in Anesthesia & Analgesia or A&A Practice. 
Section 8: EDITORIAL, ETHICAL AND LEGAL REQUIREMENTS (Back to 
Contents) 
Anesthesia & Analgesia and A&A Practice follow the International Committee of 
Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, 
Editing, and Publication of Scholarly Work in Medical Journals”. 
All authors submitting a manuscript to Anesthesia & Analgesia and A&A 
Practice are required to understand and to adhere to the material below. 
A. Role of Authors and Contributors 
Anesthesia & Analgesia and A&A Practice adhere to the ICMJE recommendations for 
defining the role of authors and non-author contributors 
Anesthesia & Analgesia and A&A Practice therefore defines manuscript authorship as 
meeting the following 4 criteria: 
1. Substantial contributions to the conception or design of the work; or the acquisition, 
analysis, or interpretation of data for the work; AND 
2. Drafting the work or revising it critically for important intellectual content; AND 
3. Final approval of the version to be published; AND 
4. Agreement to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy or integrity of any part of the work are appropriately investigated 
and resolved. 
Those individuals who do not meet all four criteria should be acknowledged as “non-
author contributors” on the Title Page of the submission, which will be printed in an 
Acknowledgement section of the published paper. 
Each manuscript must have a “Corresponding Author.” The corresponding author serves 
as the primary contact during the submission and review process on behalf of all co-
authors. Upon submission, the corresponding author is required to attest to the validity 
and legitimacy of the data and interpretation. The corresponding author is responsible for 
ensuring that all authors have reviewed the manuscript and have completed the conflict of 
interest disclosures. If the manuscript is accepted, the corresponding author is responsible 
for reviewing the proof. 
If during the manuscript review process or with a complete resubmission, an initial 





revision cover letter. The deleted or added author must be formally notified in 
writing, with a copy of this co-author correspondence sent to the Journal Editorial 
Office. 
Upon acceptance, the Editorial Office will also require a completed Authorship 
Change Verification form, finalizing the agreed upon authorship order for the 
accepted submission from each author listed, as well as, those who were added or 
removed. 
B. Author Conflict of Interest 
Anesthesia & Analgesia A&A Practice endorse the ICMJE recommendations for defining 
the role of authors’ conflict of interest. 
 Anesthesia & Analgesia A&A Practice holds that a conflict of interest exists when 
professional judgment concerning the primary interest, including patients’ welfare 
or the validity of research, may be influenced by a secondary interest like 
financial gain. Perceptions of conflict of interest are as important as actual 
conflicts of interest. 
 Authors therefore must define all funding sources supporting their work. This 
includes departmental, hospital, or institutional funds. The authors must disclose 
commercial associations that might pose a conflict of interest in connection with 
the work submitted. Financial relationships such as employment, consultancies, 
stock ownership or options, honoraria, patents, and paid expert testimony must 
also be reported. 
C. Protection of Human Subjects 
Research is a systematic investigation for the creation of generalizable knowledge. Any 
investigation submitted for publication demonstrates intent to create generalizable 
knowledge, and thus constitutes research. 
The name of the institutional research ethical review and oversight committee varies with 
country and local custom. In the United States, this committee is called the Institutional 
Review Board (IRB). Other countries may use other terms (e.g., “Research Ethics 
Committee”) for their research ethical review committee. “Institutional Review Board” is 
used here generically to refer to the local board that reviews the ethical treatment of 
human subjects and grants institutional approval for the study. 
 Regardless of the country of origin, all clinical investigators undertaking human 
subjects research must abide by the “Ethical Principles for Medical Research 
Involving Human Subjects” outlined in the Declaration of Helsinki, and adopted 





Clinical studies not meeting the Declaration of Helsinki criteria will not be considered for 
publication. If published research is subsequently found to be noncompliant, it will be 
retracted. 
 On the basis of the Declaration of Helsinki, Anesthesia & Analgesia requires that 
all manuscripts reporting clinical research state in the first paragraph of the 
Methods section that: 
1. The study was approved by the appropriate Institutional Review Board (IRB), and 
2. Written informed consent was obtained from all subjects, a legal surrogate, the parents 
or legal guardians for minor subjects, or that the requirement for written informed 
consent was waived by the Institutional Review Board (IRB). 
The Editors of Anesthesia & Analgesia may question the authors about the details of the 
IRB review, informed consent forms, or the consent process. On occasion, the Editor-in-
Chief may request a copy of the approved IRB application from the author. Lack of 
appropriate consent or its documentation will be grounds for rejection or subsequent 
retraction. 
 Patients also have a right to privacy regarding their protected health information 
(PHI). Access to their protected health information (PHI) should not occur 
without their written authorization of use or disclosure of PHI for the explicit 
purposes of (a) research or (b) a case report (N = 1) or case series (N < 3). Under 
certain circumstances, the requirement for patient written authorization may be 
waived by the Institutional Review Board (IRB). 
D. A&A Practice Compliance with United States HIPAA Privacy Regulations 
A patient’s protected health information (PHI) can be viewed and used in a clinical 
setting by those who are assisting with or learning how to provide health care to patients. 
For example, a patient’s PHI can be used internally for grand rounds or quality 
improvement and patient safety projects and related presentations. 
However, the circumstances are different in the United States if the PHI is to be shared 
outside one’s own HIPAA-covered entity’s clinical education setting. 
When making presentations outside one’s HIPAA-covered entity’s clinical education 
setting or when preparing a case report or case series (with an N ≤ 3) for publication, the 
researcher or educator must adhere to two requirements: 
1. One must remove all PHI data elements from the patient information before using 
it. If all of the 18 PHI data elements, found at http://www.hhs.gov/hipaa/for-
professionals/privacy/special-topics/de-identification/index.html#standard, are 
removed from the presentation or a case report or case series (with an N ≤ 3) for 





Take special note that one these 18 PHI data elements includes: “Any other 
unique identifying number, characteristic, or code.” This scenario includes a 
clinical case so unique that individuals with personal knowledge of the incident 
could identify the patient. In this situation, a written authorization must be 
obtained for disclosure of the PHI in a case report or case series (with an N ≤ 3) 
for publication. 
2. If a clinician, educator, or researcher must include any PHI data elements as part 
of the activity (including the above “other unique identifying characteristic”), then 
the second requirement also applies. The patient must authorize the use of their 
PHI by signing a written HIPAA-compliant authorization, which prescribes how 
their PHI will be used for a specific purpose. Examples of situations for which 
patient authorization is required include preparation of a case report or case series 
(with an N ≤ 3) for publication, a lecture to national or international professional 
meeting, and presentation to a class or seminar outside the covered entity’s 
clinical education setting. 
A case report or retrospective chart review with three (3) or fewer patients (N < 3), which 
is not presented as a systematic investigation that is designed to contribute to 
generalizable knowledge, is not considered research. Such efforts do not require 
Institutional Review Board (IRB) approval, if originating from the United States. 
A&A Practice therefore, for submissions originating from the United States, (a) 
does not require IRB approval but (b) does require that written HIPAA authorization 
(permission) is obtained from the patient (or deceased patient’s relative) for submission 
of a Clinical Case Report or Case Series for potential publication. Authors should use 
their own institutional HIPAA Authorization form for this purpose. 
This authorization must be obtained before submission of the manuscript, and the authors 
must state this authorization was obtained at the end of the introduction section. If 
photographs of the patient, in any form, are used, a specific signed permission from the 
patient must be obtained, and a copy of this signed permission be submitted with the 
manuscript. Failure to comply with these requirements will result in rejection of the 
manuscript. 
As noted above, regulations outside the United States regarding case reports or case 
series, including a requirement to obtain IRB or Research Ethics Committee approval and 
written patient consent, must be followed. 
E. A&A Practice Echo Rounds and Echo Didactics Compliance with HIPAA Privacy 
Regulations 
A patient’s protected health information (PHI) can be viewed and used in a clinical 
setting by those who are assisting with or learning how to provide health care to patients. 
For example, a patient’s PHI can be used internally for grand rounds or quality 





The circumstances are different if the PHI is to be shared outside one’s own HIPAA-
covered entity’s clinical education setting. 
When making presentations outside one’s HIPAA-covered entity’s clinical education 
setting or when preparing a case report (N = 1) (which includes an Anesthesia & 
Analgesia Echo Rounds) or case series (with an N < 3) for publication, the researcher or 
educator must adhere to two requirements: 
1. One must remove all PHI data elements from the patient information before using 
it. If all of the 18 PHI data elements, found at http://www.hhs.gov/hipaa/for-
professionals/privacy/special-topics/de-identification/index.html#standard, are 
removed from the presentation or a case report or case series (with an N ≤ 3) for 
publication, then the information is de-identified data and contains no PHI. 
Take special note that one these 18 PHI data elements includes: “Any other 
unique identifying number, characteristic, or code.” This scenario includes a 
clinical case so unique that individuals with personal knowledge of the incident 
could identify the patient. In this situation, an authorization must be obtained for 
disclosure of the PHI in a case report or case series (with an N ≤ 3) for 
publication. 
2. If a clinician, educator, or researcher must include any PHI data elements as part 
of the activity, then the second requirement applies. The patient must authorize 
the use of their PHI by signing a written HIPAA-compliant authorization, which 
prescribes how their PHI will be used for a specific purpose. Examples of 
situations for which patient authorization is required include preparation of a case 
report or case series (with an N ≤ 3) for publication, a lecture to national or 
international professional meeting, and presentation to a class or seminar outside 
the covered entity’s clinical education setting. 
A case report or retrospective chart review with three (3) or fewer patients (N < 3), which 
is not presented as a systematic investigation that is designed to contribute to 
generalizable knowledge, is not considered research. Such efforts do not require 
Institutional Review Board (IRB) approval. 
As with Case Reports (see Section 7.D above), Anesthesia & Analgesia therefore (a) does 
not require IRB approval but (b) does require that a HIPAA-compliant written 
authorization of use or disclosure of PHI, for the explicit purposes of the Echo Rounds 
manuscript, is obtained from the patient (or a deceased patient’s relative) for submission 
of an Echo Rounds for potential publication. This written authorization of use or 
disclosure of PHI must be obtained before submission of the manuscript. The author(s) 
must state they obtained this written authorization of use or disclosure of PHI in their 
submission cover letter. Failure to comply with these requirements will result in rejection 






F. Investigational Drugs 
The Editorial Board of Anesthesia & Analgesia may exercise judgment about the ethics 
of a clinical trial involving investigational drugs that differs from the view of the 
investigators’ Institutional Review Board. This situation most frequently occurs in studies 
involving neuraxial or perineural drug administration; drug studies in children; and 
nonconformity in dose, route, or indication (“off-label” use). 
 Studies using drugs injected into the neuraxial (caudal, intrathecal, or epidural) or 
perineural space must meet at least one of three criteria: 
1. The drug is approved for neuraxial or perineural administration by the United States 
(US) Food and Drug Administration (FDA) or the equivalent regulatory agency for the 
country in which the study took place. 
2. The drug is not approved for neuraxial or perineural use, but it is widely used and 
accepted for neuraxial (e.g., fentanyl) or perineural administration. The publication of 
dosing guidelines in multiple textbooks represents a reasonable demonstration that a drug 
is widely used and accepted for neuraxial or perineural administration. 
3. The study is performed under an Investigational New Drug (IND) or Biologics License 
Application (BLA) application approved by the US FDA or the equivalent agency in the 
investigator’s country. 
 Anesthesia & Analgesia is committed to expanding knowledge of the clinical 
pharmacology of drugs in children. However, studying drugs in children when 
there is no pediatric indication poses ethical concerns. Therefore, studies of drugs 
in children must meet at least one of three criteria: 
1. The drug is approved for pediatric administration by the US FDA or an equivalent 
regulatory agency. 
2. The drug is not approved for use in children but is widely used and accepted for 
pediatric administration. A reasonable demonstration that the drug is clinically accepted 
for use in children is when the administration in the study is consistent with the route, 
dose, and indication reported in multiple textbooks. 
3. The study is done under an IND application approved by the US FDA or the equivalent 
agency in the investigator’s country. Investigators in the United States are directed to the 
FDA website for further information on obtaining an investigator IND. 
Anesthesia & Analgesia will not publish a paper describing a retrospective assessment 
involving pediatric drug administration, if the treatment would be considered 





 Drugs are commonly used off-label in clinical trials, and the practice is generally 
acceptable. However, the Editorial Board of Anesthesia & Analgesia reserves the 
right not to review a manuscript describing off-label administration of a drug if 
the Editorial Board believes the study posed unacceptable risk to subjects. To 
preclude such a determination, investigators are encouraged to obtain an 
Investigator IND from the US FDA or an equivalent agency in their country 
before initiating studies involving off-label drug administration. 
G. Registration of Clinical Trials 
All clinical trials involving assignment of patients to treatment groups must be 
registered prior to the start of the trial and any patient enrollment is undertaken. 
The registry, registration number, principal investigator's name, and date of registration 
must be stated in the first paragraph of the Methods section of the manuscript. 
Authors must state in the Methods section of their manuscript that registration of 
their clinical trial occurred prior to the start of the trial and any patient enrollment 
undertaken. 
A number of registries have been approved by the International Committee of Medical 
Journal Editors (http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/), 
including http://www.clinicaltrials.gov (the most commonly used registry in the United 
States), http://isrctn.org, http://www.umin.ac.jp/ctr/index/htm, http://www.anzctr.org.au, 
and http://www.trialregister.nl. Submissions that have registered with the European 
Clinical Trials Database, EudraCT (https://eudract.ema.europa.eu/) meet this 
requirement. 
H. Protection of Animal Subjects 
Manuscripts describing investigations performed in vertebrate animals must explicitly 
state that the study was approved by the authors’ Institutional Review Board for animal 
research (e.g., Institutional Animal Care and Use Committee, IACUC). The Journal 
expects humane and ethical treatment of all experimental animals, and requires that the 
study has been conducted in a manner that does not inflict unnecessary pain or discomfort 
upon the animals, as outlined by the United States Public Health Service Policy on 
Humane Care and Use of Laboratory Animals and the Guide for the Care and Use of 
Laboratory Animals (1996), prepared by the National Academy of Sciences’ Institute for 
Laboratory Animal Research. A statement to this effect should appear at the beginning of 
the Methods section of the manuscript. 
I. Plagiarism 
Plagiarism is the use of previously published material without attribution. The Editorial 
Office screens all submitted manuscripts for plagiarism, using a sophisticated 





passages of text that have been previously published and generates a 
qualitative/quantitative report. This report is reviewed by the Journal Editorial Board and 
its support staff. 
Text copied from previously published work is interpreted using the following taxonomy: 
 Intellectual theft is misrepresentation by an author that words and ideas 
previously published by another author represent the plagiarist’s own scholarship. 
It is the most serious form of plagiarism. Intellectual theft identified during 
screening results in immediate rejection of the manuscript and a request for an 
explanation from the author. 
 Intellectual sloth is the use of the words of another author to avoid the effort of 
writing new text. It commonly occurs when descriptions of research methodology 
are taken from prior publications. It is less serious than intellectual theft, because 
the text is generic and of no particular value. Submissions containing intellectual 
sloth are typically returned to the authors with a request that the copied text either 
correctly cite the original author or be rewritten in the authors’ own words. 
 Plagiarism for scientific English occurs when authors uncomfortable using 
scientific English compose their manuscripts as a patchwork of previously 
published sentences and paragraphs. Papers constructed in such a manner are 
rejected outright, primarily because patchwork plagiarism suggests that the 
authors may not understand the text they have submitted for publication. 
 Technical plagiarism is the use of verbatim text not identified as taken verbatim, 
but simply referenced to the original source. The offense is a technical one, and 
authors are simply asked to correct it prior to peer review. 
 “Self-plagiarism” occurs when an author uses his or her verbatim words from a 
previous manuscript in a new submission. Provided the authors are not engaged in 
duplicate publication, the Journal does not view “self-plagiarism” as misconduct. 
Authors are permitted to reuse their own words, and are encouraged to do so 
when describing identical research methods in multiple papers. 
J. Duplicate Submission or Duplicate Publication 
 Duplicate submission is concurrent submission of a nearly identical manuscript to 
two journals. It is improper for authors to submit a manuscript describing 
essentially the same research simultaneously to more than one peer-reviewed 
research journal. Authors should not submit the same manuscript, in the same or 
different languages, simultaneously to more than one journal. Duplicate 
submissions identified during peer review will be immediately rejected. Duplicate 
submissions that are discovered after publication in the Journal will be retracted. 
 Duplicate publication is prior publication of a manuscript with considerable 
content overlap, particularly in the research results, by the same author or co-
authors. Prior publication may be in the same language or it may be a translation 
(usually from the author’s native language to English). Submitted manuscripts 





electronically. This includes personal, departmental, educational, or other Internet 
sites. This does not apply to abstracts of scientific meetings or to lecture handouts 
(e.g., IARS Annual Meeting, ASA Annual Meeting). Anesthesia & 
Analgesia requests that authors inform the Journal when results of a submitted 
manuscript have been previously presented or published in any venue. If a 
manuscript has been published previously, the submission to Anesthesia & 
Analgesia and A&A Practice will be rejected unless it has already been published 
by the Journal, in which case it will be retracted. 
K. Scientific Misconduct 
When Anesthesia & Analgesia has concerns or receives allegations of scientific 
misconduct, Anesthesia & Analgesia reserves the right to proceed according to the 
procedures described below. 
Anesthesia & Analgesia recognize its responsibility to appropriately address concerns 
allegations of misconduct. Examples of misconduct include: fraud, data fabrication, data 
falsification, plagiarism, improper designations of authorship, duplicate publication, 
misappropriation of others' research, failure to disclose conflict(s) of interest, and failure 
to comply with applicable legislative or regulatory requirements. Misconduct also 
includes failure to comply with any rules, policies, or procedures implemented 
by Anesthesia & Analgesia. 
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